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Abstract 
 
 
The classical human leukocyte antigen (HLA) class I molecules are important regulators of both 
the adaptive and innate immune responses to viral infection. Genetic variability within these loci 
determines the nature of the interaction between both the T cell receptor (TCR) on CD8+ T cells 
and specific killer immunoglobulin-like receptors (KIR) on the surface of natural killer (NK 
cell). Both of these interactions have previously been demonstrated to be important in 
determining the course of HIV-1 disease outcome. We therefore examined patterns of genetic 
variability within both of these complex gene families in individuals from the Black South 
African population group, contrasting them with genetic variability observed within the 
corresponding loci in Caucasian South Africans and demonstrated associations between specific 
genetic variants within the HLA and KIR gene complexes and HIV-1 control in the Black South 
African population. 
 
Examination of genetic diversity within the KIR gene complex in the Black and Caucasian 
South African population groups revealed these two population groups differed significantly 
with respect to their KIR2DS1 and KIR3DS1 gene frequencies, as well as with respect to the 
full-length (KIR2DS4f) and truncated (KIR2DS4v) forms of KIR2DS4. Like KIR2DS1 and 
KIR3DS1, KIR2DS4v was most frequently observed in the Caucasian population group, while 
KIR2DS4f  was more frequently observed within the Black population group. These differences 
could be attributed to the different frequency distributions of specific telomeric KIR haplotype 
motifs within these two population groups. These findings are of particular importance in the 
South African context, given the associations of KIR2DS4 and KIR3DS1 with both HIV-1 
transmission  and disease progression. 
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An insertion-deletion (indel) polymorphism within the 3' untranslated region (UTR) of HLA-C 
has also been shown to be involved in the regulation of HLA-C expression. Individuals who 
carry a deletion at this position exhibit increased HLA-C expression, which associates with 
lower viral set point in HIV-1 infected individuals. This 263 indel (rs67384697) is reported to 
be in strong linkage disequilibrium (LD) with a single nucleotide polymorphism (SNP) 35 
kilobases upstream of HLA-C (-35T/C; rs9264942) in Caucasian individuals, making this SNP a 
potential marker for both HLA-C expression and HIV-1 disease progression. We therefore 
examined genetic variation within the UTRs of the HLA-C alleles present in Black and 
Caucasian South Africans and identified two overlapping haplotypes encompassing the 263 
indel and another indel at position 230 in both populations, which we propose may act in 
concert to regulate levels of HLA-C expression. Concomitant evaluation of variability at the -35 
SNP revealed this polymorphism to be an inappropriate marker for either indel in these 
populations.  
 
Recently, individual polymorphic amino acids within the classical HLA class I loci, located 
predominantly within the peptide binding groove, have been shown to be strongly associated 
with HIV-1 control. We, therefore, examined patterns of genetic variability within and across 
the HLA class I loci in Black South African HIV-1 progressors and –controllers. Our findings 
confirmed those from other populations, demonstrating the importance of HLA-B residues 67, 
70, 97 and 116 in determining disease outcome, while also identifying additional residues in 
HLA-A and -B that may potentially contribute to determining differential disease outcome in 
this population. Variability at these residues likely impacts the specificity of the peptide bound 
by the HLA molecule, resulting in differential regulation of both cytotoxic T lymphocyte (CTL) 
and natural killer (NK) cell responses. No significant associations were observed between HIV-
1 control and variability within either the HLA-C peptide binding groove or the 3’ UTR.  
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Finally, we examined the role of genetic variability within the KIR gene complex in regulating 
HIV-1 control by examining patterns of genetic variability within this locus in Black South 
African HIV-1 progressors and –controllers. We found loss of control to be significantly 
associated with specific KIR haplotype motifs lacking KIR2DS4 and KIR3DL1, while 
maintenance of viral control was found to be associated with possession of KIR haplotypes 
containing the centromeric cB01 motif. Furthermore, elite controllers were more frequently 
found to be in possession of cB01 motifs containing KIR2DS5, rather than KIR2DS3. In light of 
the strong linkage disequilibrium observed across this region, KIR2DS3 and KIR2DS5 are 
thought act as markers for specific allelic variants of the inhibitory receptors KIR2DL1 and 
KIR2DL2, which are known to mediate differential inhibition of NK cell function. 
 
Collectively, these data represent the first comprehensive description of genetic variability 
within the KIR gene complex in Black South Africans and provide the valuable insights into the 
role of these receptors in mediating control of HIV-1 infection through interaction with their 
HLA class I -encoded ligands. 
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Chapter 1 
Introduction 
 
 
To date it is estimated that more than 60 million people worldwide have been infected with 
HIV-1, with 35 million people currently thought to be living with the virus (UNAIDS, 2015). 
Most individuals are thought to exhibit a similar disease course, characterized by an 
asymptomatic period of eight to ten years following the initial phase of acute infection, during 
which ongoing viral replication induces immune dysregulation and eventually death (Deeks and 
Walker, 2007). However, subsets of individuals who exhibit extreme rates of disease 
progression have been identified.  
 
One such group, termed HIV-1 controllers, includes individuals able to spontaneously suppress 
viral replication and maintain very low levels of viraemia (< 2000 RNA copies/ml) in the 
absence of highly active antiretroviral therapy (Walker and Yu, 2013). Within this group, a still 
smaller percentage of individuals, known as elite controllers, can be further distinguished from 
other HIV-1 controllers by their ability to suppress viral replication to virtually undetectable 
levels (Deeks and Walker, 2007). While the ability of these individuals to suppress viral 
replication has been shown to be associated with a number of both viral and host genetic 
characteristics - suggesting that control of HIV-1 viral replication is mediated by multiple 
immunological mechanisms - it is hoped that identification and characterization of immune 
signatures that distinguish controllers from other HIV-1 infected individuals will aid in the 
identification of future therapeutic targets (Deeks and Walker, 2007; Walker and Yu, 2013). 
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1.1 Genetic Variation in Africans 
The importance of differences in genetic variation within and between individuals in 
determining disease outcome is becoming increasingly apparent (Hirschhorn et al., 2002). What 
is also becoming clear, is that geographically distinct populations with differing demographic 
histories often display marked differences in patterns of genetic variability (Rosenberg et al., 
2002; Conrad et al., 2006). These differences are often most pronounced when comparisons are 
drawn between African and non-African populations, as African populations often exhibit 
increased levels of genetic variability relative to their non-African counterparts (Tishkoff and 
Williams, 2002). Africans also typically display lower levels of linkage disequilibrium (LD) 
than non-African populations (Reich et al., 2001), with the result that African populations 
exhibit greater haplotypic diversity (Stephens et al., 2001; Conrad et al., 2006). This has been 
attributed to the fact that African populations have consistently maintained a larger effective 
population size than non-African populations, which have been subject to extensive genetic drift 
as a consequence of having undergone bottleneck and founder effects following the migration 
out of Africa (Quintana-Murci et al., 1999).  
 
It is now well established that genetic variation plays an important role in determining an 
individual’s susceptibility to disease (Tishkoff and Verrelli, 2003). Differential disease 
susceptibilities and rates of disease progression between African and non-African populations, 
stemming from differences in patterns of genetic variability between these population groups, 
have been described for a number of complex diseases (Campbell and Tishkoff, 2008). 
Differences in patterns of genetic variability between African and non-African populations are 
also becoming increasingly apparent within genes influencing HIV-1 transmission and disease 
outcome (Gonzalez et al., 2001; Han et al., 2008; Pelak et al., 2010). Many of these genes 
encode products that are involved in viral entry into the cell, immune recognition and antigen 
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presentation, and as a result, polymorphic variations in these genes can have profound effects on 
host-pathogen interactions (Winkler et al., 2004; Kaslow et al., 2005; Brass et al., 2008).  
1.2 The Human Leukocyte Antigen (HLA) Complex 
Genetic variability within the human leukocyte antigen (HLA) complex has been identified as 
one of the major determinants of HIV-1 control (Fellay et al., 2007; The International HIV 
Controller Study, 2010). The HLA class I loci, HLA-A, HLA-B and HLA-C, are located within 
the major histocompatibility complex (MHC), situated on the short arm of chromosome 6 (The 
MHC sequencing consortium, 1999) and are the most polymorphic genes in the human genome 
(Robinson et al., 2014). These genes encode membrane-bound glycoproteins, found on the 
surface of all nucleated cells and platelets (Fleming et al., 1981), which mediate immune 
responses through their interactions with multiple cell types (Salter et al., 1990; Colonna and 
Samaridis, 1995). 
1.2.1 HLA Class I Polymorphism 
HLA molecules expressed at the cell surface are typically non-covalently linked heterodimers, 
consisting of a highly polymorphic heavy (H) chain in complex with an invariant β2-
microglobulin light chain and a short (generally 8 – 10 amino acids in length) bound peptide 
(Bjorkman et al., 1987a). The extracellular domain of the H chain is encoded within exons 2, 3 
and 4 of each gene, and is comprised of three α domains that collectively constitute the peptide-
binding groove (Bjorkman et al., 1987b). Genetic variability within these α domains determines 
both the specificity of the peptide bound by the HLA molecule (Bjorkman et al., 1987b), as well 
as the nature of the interaction between the peptide-bound HLA molecule and its cognate 
receptors (Salter et al., 1990; Fadda et al., 2011). 
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1.2.2 HLA Class I Function 
HLA class I molecules bind both the αβ T cell receptor (TCR) found on the surface of CD8+ T 
cells (Salter et al., 1990), as well as specific killer immunoglobulin-like receptors (KIR) 
expressed (predominantly) on the surface of natural killer (NK) cells (Lanier, 1998). The 
binding sites for the TCR and inhibitory KIR receptors within HLA class I molecules are 
encoded within overlapping regions of the highly polymorphic α1 domain (Figure 1.1; 
Boyington and Sun, 2002). This overlap is anticipated to result in competing selective pressures 
being exerted on the HLA class I loci by the adaptive and innate immune responses (Older 
Aguilar et al., 2010). As a counter-measure to this, human-specific evolution of the KIR loci 
encoding inhibitory receptors has resulted in reduced affinity for HLA-A and –B, while 
diversifying the interaction between these receptors and HLA-C (Older Aguilar et al., 2010; 
Parham, 2012). Consequently, while HLA-B has emerged as the dominant regulator of 
cytotoxic T lymphocyte (CTL) responses (Bihl et al., 2006), binding of HLA-C to inhibitory 
KIR is thought to be the interaction primarily responsible for regulating NK cell function 
(Moesta and Parham, 2012). 
 
Figure 1.1: The TCR and KIR binding sites occur within overlapping regions of the HLA class 1 α 
domains. The KIR and TCR binding sites are indicated in red and green, respectively. 
Image modified from Parham (2012). 
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1.2.3 The Dominant Influence of HLA-B on HIV-1 Control 
Allelic variability within HLA-B has repeatedly been shown to be strongly associated with the 
rate of HIV-1 disease progression. While multiple alleles have been shown to be associated with 
differential rates of HIV-1 disease progression (Costello et al., 1999; Kiepiela et al., 2004; 
Frahm et al., 2005; Lazaryan et al., 2006; Honeybourne et al., 2007; Lazaryan et al., 2010; 
Leslie et al., 2010; Tang et al., 2011), the HLA-B*57 alleles (B*57:01:01, B*57:02:01 and 
B*57:03:01) in particular have consistently been shown to be strongly associated with HIV-1 
control (Kiepiela et al., 2004; Costello et al., 2008; Leslie et al., 2010; The International HIV 
Controller Study, 2010; McLaren et al., 2012). These associations are thought to be 
predominantly as a result of targeting of specific immunodominant epitopes in Gag early in 
infection (Zuñiga et al., 2006). 
 
Consistent with the dominant influence of HLA-B in the regulation of CTL responses is the 
recent identification of specific residues encoded within the HLA-B α domains that have been 
shown to strongly associate with HIV-1 control (The International HIV Controller Study, 2010; 
McLaren et al., 2012). These residues are involved in determining the structural integrity of the 
peptide-binding groove, as well as mediating the interaction with the bound peptide (Bjorkman 
et al., 1987b). Specificity of the peptide bound by HLA class I molecules not only determines 
the nature of their interactions with their cognate receptors (Fadda et al., 2011), but also limits 
their capacity to elicit CTL responses due to reductions in their surface expression (Rizvi et al., 
2014). 
 
The roles of HLA-A and HLA-C in mediating control of HIV-1 infection can also not be 
discounted. As a result of the presence of strong LD across the HLA gene complex, HLA-B 
alleles associated with differential HIV-1 disease progression are commonly found to occur in 
combination with specific HLA-A and HLA-C alleles (Kiepiela et al., 2004; Leslie et al., 2010; 
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Tang et al., 2011) and while the effects of these haplotypes are often attributed solely to 
functional interactions mediated through HLA-B, there is evidence to support the idea that these 
allelic combinations may act in concert and contribute additively to differentially regulate HIV-
1 disease progression (Leslie et al., 2010). 
 
1.2.4 The Influence of HLA-C Expression on HIV-1 Control 
Genome-wide association studies (GWAS) have shown a single nucleotide polymorphism 
(SNP) 35 kilobases (kb) upstream of HLA-C to be strongly associated with HIV-1 control 
(Fellay et al., 2007; Fellay et al., 2009. This SNP (-35T/C; rs9264942) also strongly associates 
with differences in HLA-C mRNA (Stranger et al., 2005; Fellay et al., 2007) and cell surface 
expression levels (Thomas et al., 2009). However, while these associations have consistently 
been shown in Caucasian cohorts (Fellay et al., 2007; Dalmasso et al., 2008; Fellay et al., 2009; 
Thomas et al., 2009; van Manen et al., 2009; The International HIV Controller Study, 2010; 
Ballana et al., 2012), the association between the -35 SNP and HIV-1 viral set point has not 
been shown to be significant in African American cohorts - despite the presence of this SNP in 
this population (Han et al., 2008; Shrestha et al., 2009; The International HIV Controller Study, 
2010; Apps et al., 2013). This has lead to the suggestion that the -35 SNP is not the causative 
variant responsible for the alteration in HLA-C expression and viral set point, but rather acts as 
a marker, in Caucasian populations, for another functionally relevant polymorphism.  
 
A single base pair insertion-deletion (indel) polymorphism at position 263 of the HLA-C 3' 
untranslated region (UTR) has since been identified that has been shown to be in strong LD with 
the -35 SNP in Caucasian individuals (Kulkarni et al., 2011). Genetic variability at this position 
(263 indel; rs67384697) affects the binding of a regulatory microRNA (miRNA148a) to the 
HLA-C 3' UTR, with a deletion at this position (263del) abolishing miRNA148a binding and 
leading to increased HLA-C expression (Kulkarni et al., 2011; Kulkarni et al., 2013). The 
263del allele at this position has also been shown to be over-represented in HIV-1 controllers of 
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European descent (Kulkarni et al., 2011). Given that increased HLA-C expression is associated 
with HIV-1 viral control (Apps et al., 2013), it is thought that the changes in HLA-C expression 
associated with this allele could help to provide long-term protection against HIV-1 disease 
progression (Kulkarni et al., 2011).  
1.3 The Killer Immunoglobulin-like Receptor (KIR) Family 
1.3.1 The KIR Gene Complex 
KIR are type I integral membrane glycoproteins that are usually expressed as monomers on the 
surface of NK cells and a subset of T cells (Lanier, 1998). They are encoded by a family of 
rapidly evolving genes found on chromosome 19q13.4 (Wilson et al., 2000; Martin et al., 
2000). To date, 14 KIR genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DS1, KIR3DL2, and KIR3DL3) and 
two pseudogenes (KIR2DP1 and KIR3DP1) have been identified in humans. They are arranged 
in a head-to-tail manner, approximately 2 kb apart, within a 150 kb region called the leukocyte 
receptor complex (LRC) (Wilson et al., 2000).  
1.3.2 KIR Structure 
KIR genes typically consist of nine exons, which encode a leader sequence (exons 1 and 2), two 
or three extracellular immunoglobulin (Ig)-like domains called D0, D1 and D2 (exons 3-5), a 
stem (exon 6), transmembrane region (exon 7) and cytoplasmic tail (exons 8 and 9) (Vilches et 
al., 2000). The receptors are classified as either two-domain (KIR2D) or three-domain receptors 
(KIR3D), based on how many extracellular domains are present (Figure 1.2). They are further 
classified as either short-tailed (S) or long-tailed (L) based on the length of their cytoplasmic 
tails. Based on the presence or absence of these domain structures,  human KIR can be classified 
into four lineages (I, II, III and V; Sambrook et al., 2005). Lineage I KIR, namely KIR2DL4 
and KIR2DL5, contain the D0 and D2 extracellular domains; while KIR3DL1 and KIR3DL2 
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are classified as lineage II KIR. The remaining two- and three-domain receptors are classified as 
lineage III KIR, with KIR3DL3 being the only lineage V receptor. 
1.3.3 KIR Signalling 
KIR regulate NK cell function by modulating a delicate balance between activating and 
inhibitory signals (Lanier, 2004). Inhibitory KIR receptors have two immunoreceptor tyrosine-
based inhibition motifs (ITIMs) in their cytoplasmic tail that become phosphorylated at specific 
tyrosine residues upon ligand binding (Fry et al., 1996). These then recruit the phosphatases 
SHP-1 and SHP-2, which dephosphorylate several tyrosine kinases and inhibit NK cell-
mediated killing and the secretion of cytokines (Yusa and Campbell, 2003). Activating KIR 
receptors, on the other hand, associate with the adapter protein DAP-12 via a charged residue 
within their transmembrane region, which is subsequently phosphorylated at tyrosine residues 
within its immunoreceptor tyrosine-based activation motif (ITAM) domain (Campbell et al., 
1998). DAP-12 then recruits several tyrosine kinases that activate NK cell-mediated killing and 
signal the cell to secrete cytokines (Carr et al., 2007; Mulrooney et al., 2013). This 
generalization appears to hold true for all KIR receptors, except KIR2DL4, which has a long 
cytoplasmic tail containing an ITIM domain, but also has a charged residue within its 
transmembrane region that allows the receptor to non-covalently associate with the γ chain of 
the FcεRI when bound to HLA-G (Rajagopalan et al., 2001; Faure and Long, 2002; Kikuchi-
Maki et al., 2003).  
1.3.4 KIR Diversity 
KIR exhibit extensive genetic diversity with respect to gene content, copy number and allelic 
representation within individual genes (Uhrberg et al., 1997; Schilling et al., 2002, Hou et al., 
2012; Jiang et al., 2012). Variability in terms of KIR gene content is determined by the presence 
of two main KIR haplotypes (Uhrberg et al., 2002, Martin et al., 2004), termed A and  B, which 
are themselves the product of varying combinations of a limited number of centromeric and 
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telomeric gene content motifs (Figure 1.3; Pyo et al., 2010, Jiang et al., 2012; Vierra-Green et 
al., 2012, Pyo et al., 2013). 
 
Figure 1.2: The domain structure of KIR receptors. ITIM sequences are indicated in yellow, while 
ITAM sequences are shown in purple. Taken from Campbell and Purdy (2011). 
 
The A haplotype is characterized by the presence of the genes encoding the inhibitory receptors 
KIR2DL1 and KIR3DL1, the activating receptor KIR2DS4 and the pseudogene, KIR2DP1, 
while the B haplotype is characterized by the presence of KIR2DL5 and the genes encoding the 
activating receptors KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1 (Uhrberg et al., 
2002; Martin et al., 2004). Four genes, namely KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1, 
are common to both haplotypes and are referred to as framework genes, as they demarcate the 
boundaries of the centromeric and telomeric haplotype motifs (Wilson et al., 2000; Pyo et al., 
2010). KIR genotypes resulting as a consequence of combinations of A haplotypes are 
designated as AA genotypes, while those composed of combinations of both A and B 
haplotypes are collectively designated as Bx genotypes. The A and B haplotypes (and by 
extension the AA and Bx genotypes) are present at different frequencies in different human 
populations (Gonzalez-Galarza et al., 2011).   
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Figure 1.3: A schematic representation of the most commonly observed KIR haplotypic motifs. 
Image taken from Pyo et al., (2013). 
 
KIR diversity is also regulated at the transcriptional level. Promoter allelic polymorphism (Li et 
al., 2008) and alternative methylation patterns within promoters (Chan et al., 2003) synergize to 
mediate allele-specific KIR expression, while the presence of multiple (Trompeter et al., 2005), 
bi-directional promoters (Davies et al., 2007) allow for alternative modes of transcription 
(Stulberg et al., 2006). Collectively, these mechanisms aid in inducing clonal and stochastic 
expression of KIR on NK cells (Valiante et al., 1997), with the result that possession of a 
particular gene does not necessarily translate into expression of the receptor. 
1.3.5 KIR Ligands 
Multiple KIR receptors have been shown to bind HLA class I, with allelic polymorphism in 
both the receptor and the ligand determining the nature of the interaction. Lineage II KIR 
receptors bind HLA-A (Döhring et al., 1996; Hansasuta et al., 2004; Thananchai et al., 2007, 
Stern et al., 2008) and –B (Cella et al., 1994; Gumperz et al., 1995), while lineage III KIR bind 
predominantly HLA-C (Colonna et al., 1993; Winter and Long, 1997;  Winter et al., 1998; 
Graef et al., 2009; Moesta et al., 2010) and to a lesser extent, HLA-A (Katz et al., 2001; Graef 
et al., 2009; Liu et al., 2014). With respect to the two lineage I KIR, KIR2DL4 binds HLA-G 
(Rajagopalan and Long, 1999), while the ligand for KIR2DL5 has yet to be described. Variants 
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of this receptor have, however, been shown to be expressed at the cell surface (Estefanía et al., 
2007) and are capable of inhibiting NK cell activity (Yusa et al., 2004). 
 
HLA-A and -B molecules containing the Bw4 epitope serve as ligands for KIR3DL1 (Cella et 
al., 1994; Gumperz et al., 1995, Thananchai et al., 2007, Stern et al., 2008). This epitope is 
defined by the amino acids at positions 77-83 of the HLA α1 domain. The affinity with which 
KIR3DL1 binds HLA-Bw4 allotypes depends on whether they have a threonine (HLA-Bw4-
80T) or isoleucine (HLA-Bw4-80I) at position 80 of their amino acid sequence (Cella et al., 
1994). HLA-Bw4-80I allotypes bind KIR3DL1 with higher affinity than HLA-Bw4-80T 
allotypes (Martin et al., 2002a). Binding affinity is also determined by residues within 
KIR3DL1 (Carr et al., 2005). Despite a high degree of sequence similarity with KIR3DL1 and 
evidence of the ability to trigger NK cell activity (Carr et al., 2007), KIR3DS1 has not been 
shown to bind HLA-Bw4 (Gillespie et al., 2007). KIR3DL2 has also been shown to bind 
particular HLA-A antigens in a peptide-specific fashion (Döhring et al., 1996; Hansasuta et al., 
2004). 
 
The lineage III inhibitory receptors, KIR2DL1, KIR2DL2 and KIR2DL3 (Colonna et al., 1993; 
Winter and Long, 1997, Winter et al., 1998), and the activating receptor KIR2DS1 (Stewart et 
al., 2005; Moesta et al., 2010) are known to bind to HLA-C allotypes. The specificities of these 
interactions are determined at positions 77 and 80 in HLA-C (Biassoni et al., 1995; Winter et 
al., 1998) and position 44 within the KIR receptors (Winter and Long, 1997). HLA-C molecules 
with an asparagine at position 80 are designated as HLA-C1; whereas those with a lysine at 
position 80 are referred to as HLA-C2 (Biassoni et al., 1995; Winter et al., 1998). KIR with a 
methionine residue at position 44 (KIR2DL1) will preferentially bind HLA-C2, while KIR with 
lysine at this position (KIR2DL2 or KIR2DL3) will preferentially bind HLA-C1. However, 
while binding of KIR2DL1 to HLA-C is limited to HLA-C2, KIR2DL2 and KIR2DL3 can bind 
both HLA-C1 and –C2 epitopes. However, the binding of HLA-C1 to these receptors occurs 
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with reduced avidity and induces less effective inhibition of NK cell-mediated cytotoxicity than 
that of HLA-C2 binding (Moesta et al., 2008; Hilton et al., 2012). While KIR2DS2 is not 
known to bind HLA-C (Moesta and Parham, 2012), is has recently been shown to bind HLA-A2 
(Liu et al., 2014). 
1.3.6 The Role of KIR-HLA Ligand Interactions in HIV-1 Control 
A role for KIR-HLA interactions in determining the course of HIV-1 disease outcome was first 
described following the observation that the co-occurrence of KIR3DS1 and HLA-Bw4-80I is 
associated with delayed HIV-1 disease progression (Martin et al., 2002a). Despite there being 
no evidence to support binding of HLA-Bw4-80I to KIR3DS1 (Carr et al., 2007; Gillespie et 
al., 2008), there is an expansion of KIR3DS1+ cells during acute HIV-1 infection (Alter et al., 
2009) and KIR3DS1+ cells have been shown to induce lysis of HIV-1 infected cells (Alter et al., 
2007).  
 
KIR3DL1 was similarly shown to be associated with control of HIV-1 infection in the presence 
of HLA-Bw4-80I (Martin et al., 2007). Based on their surface expression, KIR3DL1 alleles can 
be classified as either high expressing (KIR3DL1*h), low expressing (KIR3DL1*l) or non-
expressed (KIR3DL1*004) (Gardiner et al., 2001; Pando et al., 2003; Thomas et al., 2008). 
KIR3DL*h/KIR3DL*h and KIR3DL1*h/KIR3DL1*004 genotypes (collectively referred to as 
KIR3DL1*h/*y) have been shown to be associated with protection against HIV-1 disease 
progression in the presence of HLA-Bw4-80I, particularly when the HLA-Bw4 molecule in 
question is HLA-B*57 (Martin et al., 2007). 
 
NK cells from HIV-1 slow-progressors with KIR3DL1 in combination with HLA-Bw4 show 
greater functionality than those from individuals without Bw4 (Kamya et al., 2011). This is 
largely thought to be due to Bw4 licensing of KIR3DL1+ NK cell licensing, with the result that 
individuals with HLA-Bw4 who express KIR3DL1 on the surface of their NK cells exhibit an 
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increased capacity for antibody-dependent cellular cytotoxicity (ADCC) relative to individuals 
without HLA-Bw4 (Parsons et al., 2010; Parsons et al., 2012). This increase in functional 
potential is highest in individuals with the KIR3DL1*h/*y/B*57 genotype (Boulet et al., 2010; 
Kamya et al., 2011) and NK cells from these individuals are better able to inhibit HIV-1 
replication in autologous CD4+ T cells than those from individuals homozygous for Bw6 or in 
possession of KIR3DL1*l alleles (Song et al., 2014). The KIR3DL1*h/*y genotype in 
combination with HLA-Bw4-80I has also be shown to be associated with strong NK responses 
in elite controllers with reduced HIV-1 Gag-specific CD8+ T cell responses (Tomescu et al., 
2012).  
 
Additional associations between KIR receptors recognizing HLA-C and HIV-1 disease course 
have since been noted (Gaudieri et al., 2005; Tiemessen et al., 2010; Tiemessen et al., 2011; 
Jennes et al., 2011; Merino et al., 2014). KIR B haplotypes containing KIR2DL2 have been 
found to be associated with lower CD4+ T cell counts in both Caucasian Australians (Gaudieri et 
al., 2005) and West Africans (Jennes et al., 2011), while expression of functional KIR2DS4 has 
been seen to promote HIV-1 pathogenesis during chronic infection (Merino et al., 2014). In 
addition, individuals who exhibit NK cell responses to HIV-1 peptides are more likely to 
possess KIR2DL3 in combination with HLA-C1 (Tiemessen et al., 2011) and these NK 
responses have been shown to be associated with lower viral loads in Black South African 
women (Tiemessen et al., 2010). 
1.4 Study Objectives 
While patterns of genetic variability within HLA class I loci in the Black and Caucasian South 
African population groups had previously been reported prior to the commencement of this 
study (Paximadis et al., 2012), no corresponding data regarding variability within the genes 
encoding their cognate KIR receptors were available. Furthermore, while the extent of genetic 
diversity of HLA-C alleles present in these population groups had been established, their 
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relationship to markers of HLA-C expression had not. Given the demonstrated roles for these 
molecules in controlling HIV-1 infection in other populations (Martin et al., 2007; Kulkarni et 
al., 2011), it was further necessary to assess the association between the observed patterns of 
genetic variability within these loci and HIV-1 control in the Black South African population – 
a population group heavily affected by the HIV-1 pandemic. The objectives of this study were 
therefore: 
 
1. To characterize patterns of genetic variability within the KIR gene complex in the 
Black and Caucasian South African populations 
2. To describe patterns of genetic variability at polymorphic positions associated with 
differential HLA-C expression in the Black and Caucasian South African 
populations 
3. To identify genetic variants within HLA class I loci associated with HIV-1 control 
in the Black South African population 
4. To identify genetic variability within the KIR gene complex associated with HIV-1 
control in the Black South African population 
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Chapter 2 
The Distribution of Killer Cell Immunoglobulin-like Receptor 
(KIR) Genes and Their HLA Class I Ligands in Two 
Ethnically Distinct South African Populations 
 
2.1 Introduction 
 
The KIR receptors are a family of glycoprotein receptors involved in the regulation of NK cell 
function. These receptors are encoded by 14 genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, 
KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, 
KIR3DL3 and KIR3DS1) and two pseudogenes (KIR2DP1 and KIR3DP1) located on 
chromosome 19 (Wilson et al., 2000; Martin et al., 2000), which exhibit extensive genetic 
diversity with respect to gene content, copy number and allelic representation within individuals 
genes (Uhrberg et al., 1997; Hou et al., 2012; Jiang et al., 2012).  
 
Variability in terms of KIR gene content is determined by the presence of two main KIR 
haplotypes (Uhrberg et al., 2002; Martin et al., 2004), which are themselves the product of 
varying combinations of a limited number of centromeric and telomeric gene content motifs 
(Jiang et al., 2012; Vierra-Green et al., 2012; Pyo et al., 2010; Pyo et al., 2013). The A 
haplotype is defined by the presence of KIR2DL1, KIR2DL3, KIR2DS4, KIR3DL1 and 
KIR2DP1, while the more variable B haplotype includes KIR2DL2, KIR2DL5, KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1 in varying combinations. These two human-
specific haplotypes are subject to balancing selection (Parham et al., 2012) and are present in all 
human populations (Yawata et al., 2002; Gendzekhadze et al., 2006), thereby maintaining the 
equilibrium between immune defense and reproductive success (Parham et al., 2012). 
 
  
16 
KIR regulate NK cell activity through interaction with their specific HLA class I ligands - the 
predominant interactions involving the binding of the HLA-C1 epitope to KIR2DL2 and 
KIR2DL3 and the binding of HLA-C2 to KIR2DL1 (Colonna et al., 1993; Winter and Long, 
1997; Winter et al., 1998) and KIR2DS1 (Moesta et al., 2010). In addition, KIR3DL1 is known 
to bind HLA-Bw4 epitopes (Cella et al., 1994; Gumperz et al., 1995; Thananchai et al., 2007; 
Stern et al., 2008), while HLA-A*03 and A*11 have been shown to bind KIR3DL2 (Döhring et 
al., 1996; Hansasuta et al., 2004). HLA-A*11 is also known to interact with both KIR2DS2 
(Liu et al., 2014) and KIR2DS4 (Graef et al., 2009) – which also recognizes a subset of HLA-C 
alleles (Katz et al., 2001;  Graef et al., 2009).  
 
Genetic diversity at the KIR loci has been shown to be associated with disease susceptibility and 
outcome (Khakoo et al., 2004; Dring et al., 2011; Hirayasu et al., 2012), autoimmunity (Martin 
et al., 2002a; Hou et al., 2009), complications during pregnancy (Hiby et al., 2004; Hiby et al., 
2008) and transplantation success (Giebel et al., 2003; Hsu et al., 2005). Of particular interest in 
a South African context, is the association seen between KIR-HLA receptor-ligand interactions 
and HIV-1 transmission (Paximadis et al., 2011; Hong et al., 2013) and disease outcome 
(Martin et al., 2002a; Martin et al., 2007). 
 
However, the distributions of both these gene families are known to vary, often dramatically, 
between geographically and ethnically distinct populations (Yawata et al., 2002; Gendzekhadze 
et al., 2006; Norman et al., 2013; Guinan et al., 2010), a factor, which if unrecognized, could 
confound later association studies. Therefore, in order to better understand patterns of genetic 
diversity within the KIR gene complex in the South African population, we examined genetic 
variability within these genes and the genes encoding their associated HLA class I ligands in 167 
Black and 97 Caucasian South Africans.  
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2.2 Materials and Methods 
2.2.1 Study Populations 
A total of 264 unrelated individuals were selected in order to describe patterns of genetic 
variability within the KIR gene cluster in the South African population. These 167 Black and 97 
Caucasian South Africans were selected from a larger previously described cohort (Paximadis et 
al., 2012) on the basis of a non-reactive HIV enzyme-linked immunosorbent assay (ELISA) test 
(Genscreen HIV1/2 version 2; Bio-Rad, Marnes-La-Coquette, France). The DNA used for 
genotyping these individuals was extracted from buffy coat samples using the PEL-FREEZ 
DNA Isolation Kit (DYNAL Invitrogen Corporation, Carlsbad, California, USA). Informed 
consent was obtained from all study participants and the study was approved by the University 
of the Witwatersrand Committee for Research on Human Subjects (Appendix B). 
 
2.2.2 KIR Genotyping 
Individuals were genotyped for the presence or absence of the 14 KIR genes (KIR2DL1, 
KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, 
KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3 and KIR3DS1) and the 2 pseudogenes (KIR2DP1 and 
KIR3DP1) using a previously described real-time PCR assay (Hong et al., 2011). Additional 
primers (Jiang et al., 2012) were included to distinguish between KIR2DS4 alleles encoding the 
full length form of the receptor (KIR2DS4*0010101-00103 – designated as KIR2DS4f) and 
alleles encoding a deleted form of the gene (KIR2DS4*003, *004, *006, *007 and *009 – 
designated as KIR2DS4v) - which differ on the basis of the presence or absence of a 22 bp 
deletion in exon 5. 
 
Reactions were performed in a 5 µl volume, containing 2x Maxima SYBR Green/ROX qPCR 
Master Mix (Fermentas, Burlington, Canada), 0.2 µM of KIR-specific primers, 0.2 µM of 
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galactosylceramidase-specific primers and 5 ng of DNA. Thermocycling was performed using 
the Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems, Foster City, 
California, USA), under the following conditions: 95°C for 10 minutes, followed by 30 cycles 
of 95°C for 15 seconds and 60°C for 1 minute, with subsequent melt curve analysis. 
 
2.2.3 KIR Genotype Assignment 
Individuals were assigned either AA or Bx KIR genotypes, according to the guidelines and 
nomenclature stipulated by the Allele Frequency Net Database (Gonzalez-Galarza et al., 2011). 
AA KIR genotypes were defined as consisting of the four framework genes (KIR2DL4, 
KIR3DL2, KIR3DL3 and KIR3DP1), in combination with KIR2DL1, KIR2DL3, KIR2DS4, 
KIR2DP1 and KIR3DL1; while Bx genotypes were defined by the presence of any one or more 
of the following genes:  KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1. 
 
2.2.4 KIR Haplotype Estimation 
In order to further elucidate the haplotypic composition of the KIR genotypes identified, 
individual KIR haplotypes were inferred using HAPLO-IHP (Yoo et al., 2007). This program 
was developed to allow for the inference of haplotypic structure from presence-absence 
genotype data, specifically in instances where information regarding gene copy number may be 
limited or entirely unavailable. This software also allows for the optional incorporation of 
information regarding previously identified haplotypes and haplotype patterns. As all known 
KIR haplotypes are derived from varying combinations of a limited number of centromeric and 
telomeric haplotype motifs (Pyo et al., 2010; Jiang et al., 2012; Vierra-Green et al., 2012; 
Nakimuli et al., 2013; Norman et al., 2013; Pyo et al., 2013), an a priori list of haplotypes 
consisting of all possible combinations of previously identified KIR haplotype motifs were 
included in these analyses.  
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The availability of gene copy number information for KIR2DS4, KIR3DL1 and KIR3DS1 
allowed haplotypes containing the tA01 telomeric haplotype motif to be resolved with a fair 
degree of certainty. However, because KIR2DL5, KIR2DS3 and KIR2DS5 can occur on both 
centromeric and telomeric KIR haplotype motifs, in the absence of copy number information for 
these genes it was impossible to distinguish between the cA01|tB01 and cB03|tB01 haplotypes 
using our haplotype estimation method. These two haplotypes are identical in gene content and 
differ only with respect to the location of the three aforementioned genes, with KIR2DL5, 
KIR2DS3 and KIR2DS5 located within the telomeric region of the cA01|tB01 haplotype and 
found within the centromeric portion of cB03|tB01 (Pyo et al., 2010; Pyo et al., 2013). The 
frequencies of these haplotypes are thus reported as cA01/cB03|tB01. 
 
2.2.5 HLA Class I Ligand Determination 
HLA-A, -B and -C genotype data were available for all 264 individuals (Paximadis et al., 2012; 
Chapter 3). HLA-A and -B Bw4 isotopes within alleles were identified based on the amino acid 
residues present at positions 77, 80, 81, 82 and 83 of the protein sequence (Martin et al., 2002a). 
A further distinction was made between HLA-B alleles with isoleucine at amino acid position 80 
(Bw4-80I) and those with threonine at this position (Bw4-80T), as these epitopes differ in the 
avidity of their interaction with KIR3DL1 (Cella et al., 1994; Martin et al., 2002a). HLA-C 
alleles were similarly classified as having either HLA-C1 or –C2 epitopes on the basis of the 
presence of asparagine or lysine at position 80, respectively (Colonna et al., 1993; Winter and 
Long, 1997). 
 
2.2.6 Statistical Analyses 
KIR gene carrier- and HLA class I ligand frequencies were determined by direct counting. KIR 
gene carrier frequencies observed within the two South African population groups were 
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compared to those previously reported for other African and Caucasian populations (Gonzalez-
Galarza et al., 2011) by complete linkage hierarchical clustering, as implemented in the hclust R 
package (www.r-project.org). The significance of differences in the frequencies observed 
between the Black and Caucasian population groups was assessed using a two-sided Fisher’s 
exact test, as implemented in R v3.1.1 (www.r-project.org). Pairwise LD between individual 
KIR loci was quantified in both population groups using the measures D’ (Lewontin, 1964) and 
r2 (Hill and Robertson, 1968) and the significance of LD between loci was assessed by an exact 
test for LD (Slatkin, 1994). LD analyses were performed using Arlequin v3.5.1.2 (Excoffier and 
Lisher, 2010). All measures were considered significant at p < 0.05.  
 
2.3 Results 
2.3.1 KIR Gene Diversity 
We examined KIR gene diversity in 167 Black and 97 Caucasian South African individuals and 
found the four framework KIR genes to be present in all 264 individuals genotyped. KIR2DL1, 
KIR2DS4, KIR3DL1 and the pseudogene, KIR2DP1, were also present in more than 98 percent 
of individuals in both population groups (Table 2.1). However, when a distinction was made 
between alleles encoding the full-length (KIR2DS4f) and truncated (KIR2DS4v) forms of 
KIR2DS4, the two population groups exhibited significantly different distributions of these two 
isoforms; with KIR2DS4f being the more frequent isoform present in the Black population 
group (p = 1.23 x 10-13) and KIR2DS4v being the most frequent in the Caucasian population 
group (p = 8.79 x 10-9). The two groups also displayed significantly different distributions of 
KIR2DS1 (p = 1.20 x 10-6) and KIR3DS1 (p = 5.43 x 10-10). While there was a tendency for 
KIR2DL2 to be more commonly observed in the Black population group, and for KIR2DL3 to 
occur with higher frequency in the Caucasian population group, these differences did not reach 
statistical significance (Table 2.1). 
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Comparison of the KIR gene carrier frequencies observed in the two South African population 
groups with those from other African and Caucasian populations (Figure 2.1) revealed the South 
African Caucasian population clustered most closely with other Caucasian populations, most 
notably those from England and the USA. Similarly, the Black South African population group 
clustered with other African populations from Uganda, Kenya and Gabon. Differences in gene 
frequency between African and Caucasian population groups were again most clearly apparent 
for KIR2DS1 and KIR3DS1, as already seen in the South African population comparison (Table 
2.1) and consistent with previous reports (Norman et al., 2013; Single et al., 2007; Nakimuli et 
al., 2013). 
 
Table 2.1: The gene carrier frequencies of the KIR genes present in the Black and 
Caucasian South African population groups 
 
KIR Gene1 
Black  
Individuals 
(n = 167) 
Caucasian 
Individuals 
(n = 97) p-value2 
 n Frequency (%) n Frequency (%)  
KIR2DL1 166 99 96 99 - 
KIR2DL2 114 68 56 58 - 
KIR2DL3 137 82 86 89 - 
KIR2DL5 102 61 49 51 - 
KIR2DS1 21 13 38 39 <0.001 
KIR2DS2 100 60 55 57 - 
KIR2DS3 44 26 23 24 - 
KIR2DS4f 139 84 37 38 <0.001 
KIR2DS4v 83 50 82 85 <0.001 
KIR2DS5 72 43 38 39 - 
KIR2DP1 166 99 96 99 - 
KIR3DL1 166 99 95 98 - 
KIR3DS1 12 7 38 39 <0.001 
 
           1
 The four framework genes (KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1) were present in all   
          individuals in both population groups and their frequencies are thus not reported here. 
            2
 p-value is for a two-sided Fisher’s exact test. Only significant values (p < 0.05) are indicated. 
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Figure 2.1: A two-dimensional heatmap based on hierarchical cluster of the carrier frequencies of 
the non-framework KIR genes in 17 African and 29 Caucasian populations. Population 
groups are clustered along the y-axis, with the South African Black (SAB) and 
Caucasian (SAC) groups indicated in red. Frequencies are indicated by the color scale, 
with higher frequencies indicated by increased color intensity. KIR loci are clustered 
along the x-axis, where A and B haplotype genes are indicated. Abbreviations: CAR = 
Central African Republic, DRC = Democratic Republic of the Congo. 
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2.3.2 KIR Genotypes Distributions 
Analysis of the KIR genotypes present in the South African population revealed the presence of 
33 KIR genotypes in the Black population group (Table 2.2). Thirteen of these were found to be 
present in more than one individual and collectively, these accounted for more than 88% of the 
genotypes observed in this population group. A total of 24 genotypes were observed in the 
Caucasian population group (Table 2.2). One of these genotypes could not be assigned an AA or 
Bx identifier according to the current nomenclature, as it had not previously been reported in 
other populations (Gonzalez-Galarza et al., 2011). Consequently, it was referred to as unknown 
(Table 2.2). However, based on its gene content, it resembled the Bx genotypes, particularly Bx 
58. The AA 1 genotype was the most prevalent in both population groups and was also present 
at similar frequencies in both groups. The Bx 2 (p = 9.33 x 10-5) and Bx 3 (p = 2.50 x 10-4) 
genotypes were significantly more frequent in the Caucasian population group, while Bx 5 (p = 
0.035), Bx 20 (p = 0.029), Bx 21 (p = 0.001) and Bx 228 (p = 0.035) were observed at 
significantly higher frequencies in the Black population group. 
 
2.3.3 KIR Haplotype Estimation 
Estimation of the KIR gene content haplotypes present in the South African population 
identified a total of 24 haplotypes across both population groups (Table 2.3). Of these, five were 
unique to the Black population group, while three were only observed in Caucasian individuals. 
The cA01|tA01 haplotype was the most common haplotype observed in both population groups 
and was present at similar frequencies in both groups. The 49% frequency seen in the South 
African Caucasian population was slightly lower than that reported for other populations of 
European descent (Pyo et al., 2010; Jiang et al., 2012; Vierra-Green et al., 2012), while the 
frequency in the Black population group was also lower than that reported in Ghanaians (48% 
versus 53%; Norman et al., 2013).  
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Table 2.2 The KIR genotype profiles identified within the South African population and 
their frequencies in the Black and Caucasian population groups  
 
KIR 
Genotype1 
K
IR
2D
L4
 
K
IR
3D
L2
 
K
IR
3D
L3
 
K
IR
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P1
 
K
IR
2D
P1
 
K
IR
2D
L1
 
K
IR
2D
L3
 
K
IR
2D
S4
 
K
IR
3D
L1
 
K
IR
2D
L2
 
K
IR
2D
L5
 
K
IR
2D
S1
 
K
IR
2D
S2
 
K
IR
2D
S3
 
K
IR
2D
S5
 
K
IR
3D
S1
 Frequency 
Black 
Individuals 
(n = 167) 
Frequency 
Caucasian 
Individuals 
(n = 97) 
AA 1                 0.269 (45)2 0.278 (27) 
Bx 21                 0.114 (19) 0.010 (1) 
Bx 4                 0.090 (15) 0.155 (15) 
Bx 5                 0.090 (15) 0.021 (2) 
Bx 228                 0.072 (12) 0.010 (1) 
Bx 20                 0.054 (9) - 
Bx 71                 0.042 (7) 0.041 (4) 
Bx 9                 0.036 (6) - 
Bx 6                 0.030 (5) 0.062 (6) 
Bx 112                 0.030 (5) - 
Bx 32                 0.024 (4) - 
Bx 51                 0.018 (3) - 
Bx 31                 0.012 (2) - 
Bx 2                 0.006 (1) 0.113 (11) 
Bx 3                 0.006 (1) 0.103 (10) 
Bx 7                 0.006 (1) 0.021 (2) 
Bx 11                 0.006 (1) - 
Bx 19                 0.006 (1) - 
Bx 25                 0.006 (1) - 
Bx 30                 0.006 (1) - 
Bx 44                 0.006 (1) - 
Bx 48                 0.006 (1) 0.010 (1) 
Bx 62                 0.006 (1) - 
Bx 64                 0.006 (1) 0.010 (1) 
Bx 73                 0.006 (1) 0.010 (1) 
Bx 81                 0.006 (1) - 
Bx 89                 0.006 (1) 0.031 (3) 
Bx 92                 0.006 (1) 0.010 (1) 
Bx 169                 0.006 (1) - 
Bx 172                 0.006 (1) 0.010 (1) 
Bx 175                 0.006 (1) - 
Bx 270                 0.006 (1) - 
Bx 393                 0.006 (1) - 
Bx 13                 - 0.021 (2) 
Bx 70                 - 0.021 (2) 
Bx 10                 - 0.010 (1) 
Bx 15                 - 0.010 (1) 
Bx 24                 - 0.010 (1) 
Bx 58                 - 0.021 (1) 
Bx 382                 - 0.010 (1) 
Unknown                 - 0.010 (1) 
 
                 1 KIR genotypes are ordered based on their frequency within the Black South African population group. 
                 2 The number of individuals in possession of each genotype, in each population group, is given in brackets. 
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The two population groups displayed significant differences in frequency for six other 
haplotypes (Table 2.3), including cB01|tA01 and four other haplotypes derived from it, 
following gene deletions or insertions (Pyo et al., 2013). While it was not possible to distinguish 
between the cA01|tB01 and cB03|tB01 haplotypes using our haplotype estimation method, 
based on the frequencies of these haplotype motifs observed in other populations (Pyo et al., 
2010; Jiang et al., 2012; Vierra-Green et al., 2012; Norman et al., 2013; Pyo et al., 2013), we 
would anticipate the majority of haplotypes with these gene content configurations to be 
cA01|tB01. Nonetheless, frequencies for these haplotypes were reported as cA01/cB03|tB01 
(Table 2.3). These haplotypes were found at significantly greater frequency in the Caucasian 
population group. 
 
While the centromeric cA01 motif was found to occur at similar frequencies in the Black (53%) 
and Caucasian (51%) population groups, at frequencies comparable with the centromeric B 
motif (cB01, cB02 and cB03), the telomeric motifs tA01 and tB01 displayed significantly 
different frequencies within the two groups (Table 2.4). While tA01 was clearly the dominant 
telomeric motif present in both groups, an increased frequency of tB01 in the Caucasian 
population distinguished the two groups. In addition, significantly more Caucasian individuals 
were found to possess tA01 motifs bearing non-functional KIR2DS4 alleles (tA01v; Table 2.4). 
tA01 motifs lacking any form of KIR2DS4 were more prevalent in the Black population group 
(tA01-hybd1; Table 2.4). 
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Table 2.3 The frequencies of the KIR haplotypes occurring in the Black and Caucasian 
South African population groups 
 
KIR Haplotype 
Black 
 Individuals 
(n = 167) 
Caucasian 
Individuals 
(n = 97) 
 
p-value1 
 n Frequency n Frequency  
cA01|tA012 159 0.476 95 0.490 - 
cA01|tA01-hybd1 9 0.027 1 0.005 - 
cA01|tA01-del5 8 0.024 2 0.010 - 
cA01/cB03|tB013 2 0.006 25 0.129 < 0.001 
cB01|tA01 57 0.171 10 0.052 < 0.001 
cB01|tA01-hybd1 14 0.042 0 0.000 0.003 
cB01|tA01-ins4 0 0.000 5 0.026 0.006 
cB01|tA01-del3 14 0.042 0 0.000 0.003 
cB01|tA01-del3-ins4 0 0.000 1 0.005 - 
cB01|tA01-del3-del5 1 0.003 0 0.000 - 
cB01|tA01-del3-del5-del9 1 0.003 0 0.000 - 
cB01|tA01-del9 32 0.096 33 0.170 0.012 
cB01|tA01-del4-del9 2 0.006 5 0.026 - 
cB01|tA01-del10 2 0.006 0 0.000 - 
cB01|tB01 9 0.027 11 0.057 - 
cB01|tB01-del5 1 0.003 0 0.000 - 
cB01|tB01-del7 8 0.024 1 0.005 - 
cB02|tA01-ins5 1 0.003 1 0.005 - 
cB02|tA01-hybd1 3 0.009 1 0.005 - 
cB03|tA01 5 0.015 1 0.005 - 
cB03|tA01-hybd1 3 0.009 0 0.000 - 
H14 2 0.006 0 0.000 - 
H2 1 0.003 1 0.005 - 
H3 0 0.000 1 0.005 - 
 
 
           1 p-value is for a two-sided Fisher’s exact test. Only significant values (p < 0.05) are indicated. 
           2 Major haplotypes comprised of the classic centromeric and telomeric KIR motifs are indicated in grey. Minor  
         haplotypes derived from these following gene insertions, deletions and duplications are named in accordance  
         with the nomenclature of Pyo et al. (2013). 
           3 cA01|tB01 and cB03|tB01 could not be distinguished from each other and are reported as cA01/cB03|tB01. 
           4 Haplotypes that could not be named according to the aforementioned nomenclature were assigned arbitrary  
         designations based on their frequencies within the Black population group. 
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Table 2.4 The telomeric KIR haplotype motifs present in the South African population 
and their frequencies within the Black and Caucasian population groups 
 
Telomeric Motif1 
Black  
Individuals 
(n = 167) 
Caucasian 
Individuals 
(n = 97) p-value2 
 n Frequency n Frequency  
tA01 314 0.940 156 0.813 < 0.001 
     tA01f 193 0.619 45 0.288 < 0.001 
     tA01v 89 0.285 108 0.692 < 0.001 
     tA01-hybd1 30 0.096 3 0.019 0.002 
tB01 20 0.060 38 0.198 < 0.001 
 
 
              1 tA01f, tA01v and tA01-hybrd1 refer to tA01 motifs carrying KIR2DS4f alleles, KIR2DS4v alleles and no  
            KIR2DS4, respectively. 
              2 p-value is for a two-sided Fisher’s exact test. Only significant values (p < 0.05) are indicated. 
 
2.3.4 Estimation of Linkage Disequilibrium 
In order to better understand the organization of the KIR haplotypes present in the South African 
population, pairwise LD between individual KIR loci was quantified in both population groups 
using the measures D’ (Lewontin, 1964) and r2 (Hill and Robertson, 1968). As was expected, 
strong positive associations were detected between genes known to be present on the same 
haplotype motifs (Tables 2.5 and 2.6). In the Black population group, strong positive 
associations were observed between KIR2DL1, KIR2DL3, KIR2DS4 and KIR3DL1, as well as 
between KIR2DL2, KIR2DS2, KIR2DS1 and KIR3DS1 (Table 2.5). In the Caucasian population 
group a clear positive association was seen between KIR2DL2, KIR2DS2 and KIR2DS3, as well 
as between KIR2DS1, KIR2DS5 and KIR3DS1 (Table 2.6). These observations were consistent 
with previous reports in other Black and Caucasian population groups (Single et al., 2007; 
Hollenbach et al., 2012; Nakimuli et al., 2013). 
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Table 2.5 The estimated linkage disequilibrium across the KIR gene complex in the Black South African population 
 
 
 
KIR2DL1 KIR2DL2 KIR2DL3 KIR2DL5 KIR2DS1 KIR2DS2 KIR2DS3 KIR2DS4 KIR2DS5 KIR2DP1 KIR3DL1 
KIR2DL2 
D' -0.650           
r2 0.027           
p-value1 0.006           
KIR2DL3 
D' 0.647 -1.000          
r2 0.026 0.976          
p-value 0.004 < 0.001          
KIR2DL5 
D' -0.691 0.163 -0.805         
r2 0.041 0.807 0.462         
p-value < 0.001 < 0.001 < 0.001         
KIR2DS1 
D' -0.787 0.750 -0.748 1.000        
r2 0.434 0.050 0.049 0.123        
p-value < 0.001 < 0.001 < 0.001 < 0.001        
KIR2DS2 
D' -0.674 0.959 -0.986 0.613 0.767       
r2 0.034 0.774 0.798 0.327 0.063       
p-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001       
KIR2DS3 
D' 0.482 0.919 -0.918 0.964 0.344 0.811      
r2 0.002 0.167 0.162 0.251 0.054 0.154      
p-value NS < 0.001 < 0.001 < 0.001 < 0.001 < 0.001      
KIR2DS4 
D' 1.000 -0.475 0.470 -0.629 -1.000 -0.511 -0.070     
r2 0.267 0.053 0.051 0.128 0.381 0.073 0.004     
p-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 NS     
KIR2DS5 
D' -0.647 0.808 -0.806 0.981 0.874 0.583 -0.337 -0.629    
r2 0.060 0.284 0.276 0.573 0.157 0.176 0.006 0.214    
p-value < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 NS < 0.001    
KIR2DP1 
D' 0.693 -1.000 1.000 0.485 -0.287 -0.963 1.000 0.118 0.259   
r2 0.149 0.203 0.198 0.020 0.036 0.224 0.022 0.012 0.003   
p-value < 0.001 < 0.001 < 0.001 0.003 < 0.001 < 0.001 < 0.001 0.040 NS   
KIR3DL1 
D' 0.709 -0.376 0.369 -0.558 -0.896 -0.302 -0.180 0.622 -0.574 0.177  
r2 0.258 0.017 0.016 0.052 0.589 0.013 0.020 0.201 0.093 0.019  
p-value < 0.001 0.023 0.023 < 0.001 < 0.001 0.017 0.003 < 0.001 < 0.001 0.019  
KIR3DS1 
D' -0.239 0.682 -0.679 1.000 1.000 0.556 0.687 -1.000 0.880 1.000 -1.000 
r2 0.041 0.021 0.020 0.062 0.508 0.017 0.109 0.193 0.081 0.005 0.372 
p-value < 0.001 0.003 0.004 < 0.001 < 0.001 0.006 < 0.001 < 0.001 < 0.001 NS < 0.001 
 
1 p-value is for an exact test of linkage disequilibrium (Slatkin, 1994). 
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Table 2.6 The estimated linkage disequilibrium across the KIR gene complex in the Caucasian South African population 
 
 
 KIR2DL1 KIR2DL2 KIR2DL3 KIR2DL5 KIR2DS1 KIR2DS2 KIR2DS3 KIR2DS4 KIR2DS5 KIR2DP1 KIR3DL1 
KIR2DL2 
D' 0.596           
r2 0.032           
p-value1 0.011           
KIR2DL3 
D' -0.625 -1.000          
r2 0.040 0.892          
p-value 0.001 < 0.001          
KIR2DL5 
D' -0.953 0.293 -0.265         
r2 0.399 0.073 0.053         
p-value < 0.001 < 0.001 0.001         
KIR2DS1 
D' -0.916 -0.015 0.086 0.965        
r2 0.591 0.000 0.001 0.581        
p-value < 0.001 NS NS < 0.001        
KIR2DS2 
D' 0.710 0.928 -0.977 0.223 -0.059       
r2 0.049 0.804 0.912 0.039 0.001       
p-value < 0.001 < 0.001 < 0.001 0.007 NS       
KIR2DS3 
D' 0.438 1.000 -1.000 1.000 0.398 0.801      
r2 0.005 0.273 0.244 0.323 0.082 0.164      
p-value NS < 0.001 < 0.001 < 0.001 < 0.001 < 0.001      
KIR2DS4 
D' 0.958 -0.005 -0.063 -0.899 -1.000 0.035 -0.390     
r2 0.607 0.000 0.001 0.537 0.940 0.000 0.074     
p-value < 0.001 NS NS < 0.001 < 0.001 NS < 0.001     
KIR2DS5 
D' -0.914 0.084 -0.048 1.000 0.871 0.063 0.269 -0.815    
r2 0.521 0.004 0.001 0.705 0.671 0.002 0.033 0.626    
p-value < 0.001 NS NS < 0.001 < 0.001 NS 0.002 < 0.001    
KIR2DP1 
D' -0.631 -1.000 1.000 0.903 0.861 -1.000 1.000 -0.736 0.874   
r2 0.016 0.447 0.399 0.075 0.042 0.417 0.030 0.033 0.049   
p-value NS < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 0.010 0.006 < 0.001   
KIR3DL1 
D' 0.872 0.062 0.002 -0.865 -0.936 0.035 -0.390 0.878 -0.784 -0.868  
r2 0.504 0.001 0.000 0.497 0.824 0.000 0.074 0.772 0.580 0.046  
p-value < 0.001 NS NS < 0.001 < 0.001 NS < 0.001 < 0.001 < 0.001 < 0.001  
KIR3DS1 
D' -0.871 0.152 -0.118 1.000 0.903 0.028 0.606 -0.846 0.824 1.000 -0.846 
r2 0.473 0.014 0.007 0.705 0.722 0.000 0.169 0.674 0.678 0.065 0.674 
p-value < 0.001 NS NS < 0.001 < 0.001 NS < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 
 
1 p-value is for an exact test of linkage disequilibrium (Slatkin, 1994).
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2.3.5 Association between Specific KIR and Their HLA Class I Ligands 
2.3.5.1 HLA-B and KIR3DL1/DS1 
The HLA-Bw4 and Bw6 epitopes are known to occur at comparable frequencies within the 
Black and Caucasian South African population groups (Paximadis et al., 2012). However, the 
frequencies with which they appear in combination with KIR3DL1, the NK cell receptor for 
HLA-Bw4, have yet to be reported for these groups. We therefore examined the proportion of 
individuals in the possession of KIR3DL1 in combination with both HLA-Bw4 and Bw6 in 
each of these population groups and found them to be similar (Table 2.7). However, Black 
individuals with alleles for both KIR3DL1 and HLA-Bw4 were more likely to carry HLA-Bw4 
alleles with isoleucine at position 80 (Bw4-80I), while Caucasian individuals more frequently 
carried alleles for HLA-Bw4 epitopes with threonine at position 80 (Bw4-80T; Table 2.7).  
 
Although KIR3DS1 - with the exception of the receptor encoded by one allele (O’Connor et al., 
2011) - has not been shown to bind HLA-Bw4 (Carr et al., 2007; Gillespie et al., 2007; 
O’Connor et al., 2007), co-occurrence of the alleles encoding these molecules has previously 
been associated with differential disease prognosis (Martin et al., 2002b; López-Vázquez et al., 
2005). We therefore also investigated the frequency with which individuals in the South African 
population possessed alleles encoding KIR3DS1 in combination with either the HLA-Bw4 or 
Bw6 epitopes (Figure 2.2). The small number of Black individuals in possession of KIR3DS1 
was most often found in possession of HLA-Bw4 alleles, while the corresponding Caucasian 
individuals were more likely to possess HLA-Bw6 alleles – although this observation did not 
reach statistical significance. In the Black population groups, as seen with KIR3DL1, KIR3DS1 
was more likely to be found in combination with alleles with HLA-Bw4-80I motifs. 
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Table 2.7 The frequency with which KIR3DL1 occurs in combination with the HLA Bw4 
and Bw6 allotypes in the Black and Caucasian South African population groups 
 
 
Black  
Individuals 
(n = 166) 
Caucasian 
Individuals 
(n = 95) p-value1 
 n Frequency2 n Frequency  
KIR3DL1 + Bw4 118 0.711 67 0.705 - 
KIR3DL1 + Bw4-80I 85 0.512 29 0.305 0.001 
KIR3DL1 + Bw4-80T 22 0.133 35 0.368 < 0.001 
KIR3DL1 + Bw6 141 0.849 78 0.821 - 
 
                   1 p-value is for a two-sided Fisher’s exact test. Only significant values (p < 0.05) are indicated. 
                   2 Frequencies are given relative to the number of individuals in each population group in possession of  
              KIR3DL1. 
 
 
 
 
Figure 2.2: The frequency with which HLA-Bw4 and -Bw6 allotypes occur in individuals from the 
Black and Caucasian South African population groups in possession of KIR3DS1. 
Frequencies are given relative to the number of individuals in each population group in 
possession of at least one copy of KIR3DS1. Significantly differences in frequency (p < 
0.05) between the two groups, as measured by a two-sided Fisher’s exact test, are 
indicated with an asterisk.  
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(a) 
 
(b) 
 
Figure 2.3: (a) The frequency with which KIR2DL1, KIR2DL2, KIR2DL3 and KIR2DS1 occur in 
combination with the HLA-C1 in individuals from the Black and Caucasian South 
African population groups. (b) The frequency with which KIR2DL1, KIR2DL2, 
KIR2DL3 and KIR2DS1 occur in combination with the HLA-C2 in individuals from the 
Black and Caucasian South African population groups. In both (a) and (b), frequencies 
are given relative to the number of individuals in each population group in possession 
of the specific HLA-C epitope of interest. Significant differences in frequency (p < 
0.05) between the two groups, as measured by a two-sided Fisher’s exact test, are 
indicated with an asterisk.  
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2.3.6 HLA-C and its Associated KIR Receptors 
The HLA-C1 and -C2 epitopes present in virtually all HLA-C alleles serve as ligands for 
KIR2DL2, KIR2DL3, KIR2DL1 and KIR2DS1 (Colonna et al., 1993; Winter and Long, 1997; 
Winter et al., 1998; Moesta et al., 2010), and occur at significantly different frequencies in the 
Black and Caucasian population groups (Paximadis et al., 2012). We therefore also examined 
the proportion of individuals in each population group who possessed the genes encoding these 
KIR receptors in the presence or absence of their respective HLA-C ligands (Figure 2.3). In 
terms of individuals found to be in possession of HLA-C1 alleles, a significantly higher 
percentage of individuals in the Black population group were also seen to possess KIR2DL2 
(Figure 2.3a). Conversely, Caucasian individuals in possession of HLA-C2 alleles were 
significantly more likely to also be in possession of KIR2DL3 (Figure 2.3b). KIR2DS1 was also 
seen to be significantly more common in Caucasian individuals with both HLA-C1 (Figure 2.3a) 
and –C2 (Figure 2.3b) than in their counterpart in the Black population group. 
 
2.4 Discussion 
We examined genetic diversity within the KIR gene complex in 167 Black and 97 Caucasian 
South African individuals and found these two population groups differed significantly with 
respect to their KIR2DS1 and KIR3DS1 gene frequencies in a manner consistent with previous 
reports describing KIR gene diversity in other African and Caucasian populations (Norman et 
al., 2007; Single et al., 2007; Nakimuli et al., 2013; Petitdemange et al., 2014). Hierarchical 
clustering analysis of gene frequencies revealed the patterns of KIR gene diversity observed in 
the Caucasian South African population closely resembled that of other Caucasian populations; 
most notably those from England and the USA. The Black South African population group, on 
the other hand, was found to most closely resemble the populations from Gabon and Uganda, as 
well as the population of predominantly Bantu-speakers from Kenya. The genetic similarity 
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observed between these populations is consistent with the proposed migration of West African 
pastoralists into southern Africa, through East Africa (Tishkoff and Williams, 2002; Henn et al., 
2008; Tishkoff et al., 2009). 
 
The differences in gene frequency observed between the Black and Caucasian population 
groups were reflected by the differences in KIR genotype frequencies observed between the two 
population groups, where genotypes including KIR2DS1 and KIR3DS1 were more commonly 
observed in the Caucasian population group and genotypes lacking these genes were most 
frequently observed in Black individuals. The commonalities in frequency distributions seen 
between these two KIR genes could be attributed to the strong pairwise LD present between 
these loci in both population groups, consistent with their co-localization on the telomeric tB01 
KIR haplotype motif (Pyo et al., 2010; Jiang et al., 2012; Vierra-Green et al., 2012; Pyo et al., 
2013). This motif has been found to be present at substantially lower frequencies than the tA01 
motif in all populations examined to date, however is reported to be present at higher 
frequencies in Caucasian populations than in African population groups (Pyo et al., 2010; Jiang 
et al., 2012; Vierra-Green et al., 2012; Norman et al., 2013; Pyo et al., 2013) - an observation 
that is consistent with our findings in the South African population.  
 
KIR2DS1 and KIR3DS1 were also seen to be in strong LD with KIR2DS5 in both population 
groups. This gene, along with KIR2DL5 and KIR2DS3, may be present on either (or both) the 
centromeric and telomeric regions of KIR B haplotypes (Pyo et al., 2010; Jiang et al., 2012; 
Vierra-Green et al., 2012; Norman et al., 2013; Pyo et al., 2013). Given the strong association 
seen between KIR2DS5, KIR2DS1 and KIR3DS1 in the Caucasian population group, coupled 
with correspondingly low levels of observed LD between KIR2DS5 and the centromeric genes, 
KIR2DL2, KIR2DL3 and KIR2DS2, it seems likely KIR2DS5 occurs predominantly on the 
telomeric region of B haplotypes, as part of the tB01 motif, in this population group. In contrast, 
strong LD between KIR2DS3 and KIR2DL2 and KIR2DS2 in this population group would 
  
35
suggest this gene occurs predominantly within centromeric motifs. This is consistent with 
previous findings in other Caucasian population groups (Single et al., 2008; Jiang et al., 2012).  
 
High levels of LD between KIR2DS3 and KIR2DL2, KIR2DL3 and KIR2DS2 in the Black 
population group, in conjunction with the observation of reduced levels of LD with KIR2DS1, 
suggest this gene also likely occurs predominantly within centromeric haplotype motifs in this 
population. Conversely, KIR2DS5 exhibited comparable level of LD with both centromeric 
(KIR2DL2 and KIR2DL3) and telomeric (KIR2DS1 and KIR3DS1) genes in the Black 
population group. This could suggest that this gene occurs within both the centromeric and 
telomeric motifs present in the Black population group at comparable frequencies, but this 
would be inconsistent with previous observations in other African populations, where KIR2DS5 
was rarely seen to occur within the telomeric motif (Nakimuli et al., 2013; Norman et al., 2013). 
Rather, this observation most likely reflects the strong LD observed between the centromeric 
and telomeric B motifs in this population group. This positional discrepancy could potentially 
be resolved with additional information regarding KIR2DS5 copy number. 
 
The Black and Caucasian South African population groups also differed with respect to 
variability in their tA01 telomeric haplotype motifs. While the majority of Black individuals 
possessed tA01 motifs containing functional, full-length KIR2DS4 alleles, most individuals in 
the Caucasian population group carried tA01 motifs with KIR2DS4v alleles. KIR2DS4v alleles 
encode a truncated receptor lacking a transmembrane domain that is not expressed at the cell 
surface (Maxwell et al., 2002). An additional 2% of Caucasians and nearly 10% of Black 
individuals were also found to possess tA01 motifs from which KIR2DS4 had been entirely 
deleted, with the result that nearly 40% of Black individuals and more than 70% of Caucasian 
individuals were in possession of tA01 motifs lacking the ability to encode a functional 
KIR2DS4 receptor and thus devoid of an activating KIR receptor.  
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While the functional significance of KIR2DS4v has yet to be elucidated, this isoform has been 
maintained at variable frequencies in populations across the world (Middleton et al., 2007) and 
represents the dominant form of the receptor present in not only the South African Caucasian, 
but also most other Caucasian populations examined to date (van der Slik et al., 2003; Denis et 
al., 2005; Du et al., 2007; Flores et al., 2007; Karlsen et al., 2007). Binding between KIR2DS4v 
and known KIR2DS4 HLA ligands has not been demonstrated (Graef et al., 2009). However, 
the observation that low levels of transcription of this variant do occur in NK cells (Middleton 
et al., 2007), as well as that possession of this isoform has been associated with disease 
susceptibility (Taniguchi and Kawabata, 2009; Zhuang et al., 2012), would suggest that its role 
in NK cell function warrants further investigation. Elucidation of KIR2DS4v function is of 
particular importance in a South Africa context, as possession of the alleles encoding these 
receptors has been associated with transmission of HIV-1 (Hong et al., 2013). 
 
The roles of other KIR receptors and their associated HLA ligands in the regulation of NK cell 
function, however, are more clear. The co-occurrence of KIR3DL1 and HLA-Bw4 epitopes 
have been shown to be associated with increased NK cell functional potential (Boulet et al., 
2010), while binding of HLA-C to KIR is thought to represent the major receptor-mediated 
mechanism responsible for the regulation of NK cell function (Moesta and Parham, 2012). We 
therefore examined the co-occurrence of genetic variability in the genes encoding these KIR 
receptors and their associated HLA ligands in the Black and Caucasian South African 
population groups. We observed that while the Black and Caucasian South African population 
groups do not differ with respect to co-occurrence of HLA-Bw4 alleles with either KIR3DL1 or 
KIR3DS1, Black individuals were significantly more likely to possess alleles containing HLA-
Bw4-80I epitopes when in possession of either KIR gene than Caucasian individuals. The 
interaction between HLA-Bw4-80I and KIR3DL1 is stronger than that between the receptor and 
HLA-Bw4-80T epitopes (Cella et al., 1994), suggesting a preference for a more inhibitory 
interaction between the KIR receptor and its HLA ligand in the Black South African population 
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group. These findings are consistent with those of a previous study examining co-evolution of 
KIR and HLA, which noted a general positive correlation between the allele frequencies of 
inhibitory KIR and their HLA ligands across 30 populations world-wide (Single et al., 2007).  
 
The correlations observed by Single et al., (2007) were also present between HLA-C alleles and 
alleles encoding their associated KIR receptors. The Black and Caucasian South African 
population groups are known to differ significantly with respect to their HLA-C1 and –C2 allele 
frequency distributions, with HLA-C1 being more prevalent in the Caucasian population and 
HLA-C2 being more frequently observed in Black individuals (Paximadis et al., 2012). We 
further noted a trend towards an increased frequency of KIR2DL2 in the Black population group 
and KIR2DL3 in the Caucasian group. It was, thus, unsurprising to find increased co-occurrence 
of KIR2DL2 and HLA-C2 in Black individuals and KIR2DL3 and HLA-C1 in Caucasian 
individuals (data not shown). Therefore, in an effort to control for potentially confounding 
associations arising from these differences in the HLA-C allele frequency distributions of these 
two population groups, KIR and HLA-C ligand interactions were evaluated separately for 
individuals in possession of HLA-C1 and those in possession of HLA-C2. This allowed us to 
observe that Black individuals in possession of HLA-C1 were significantly more likely to also 
be in possession of KIR2DL2 than their Caucasian counterparts, while Caucasian individuals 
with HLA-C2 were more likely to carry KIR2DL3 than their Black counterparts.  
 
While binding of KIR2DL1 to HLA-C is limited to HLA-C2, KIR2DL2 and KIR2DL3 can bind 
both HLA-C1 and –C2 epitopes. However, the binding of HLA-C1 to these receptors occurs 
with reduced avidity and induces less effective inhibition of NK cell-mediated cytotoxicity than 
that of HLA-C2 binding (Moesta et al., 2008; Hilton et al., 2012). This, coupled with the 
observation that KIR2DL2 binds both HLA-C1 and –C2 with greater avidity than KIR2DL3 
(Moesta et al., 2008; Hilton et al., 2012; Frazier et al., 2013), would suggest a tendency in both 
population groups towards reduced avidity between HLA-C and its KIR receptors. KIR2DS1 
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was also seen to be significantly more common in Caucasian individuals with both HLA-C1 and 
–C2 than in their counterparts from the Black population group. However it was not possible to 
establish whether this observation was representative of a true association between these genes, 
stemming from their functional interaction, or simply a consequence of the differences in 
KIR2DS1 gene frequency observed between the two population groups 
 
Collectively, these data describe patterns of genetic diversity within the KIR gene complex in 
the Black and Caucasian South African population groups, providing the first description of KIR 
haplotype content in these populations. The haplotypic differences observed between these two 
groups are of particular importance because they affect the frequency distributions of the 
disease-associated genes, KIR2DS1, KIR2DS4 and KIR3DS1 within these populations. If 
unaccounted for, these differences could potentially confound future disease association studies 
conducted within these groups. The findings regarding KIR2DS4 and KIR3DS1 are especially 
important in the South African context, given the association between these genes and HIV-1 
transmission (Merino et al., 2011; Hong et al., 2013) and disease progression (Martin et al., 
2002a; Martin et al., 2007). 
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Chapter 3 
Genetic Variability in Markers of HLA-C Expression Show 
Similarity between Two Diverse South African Populations1 
 
1 Published: Gentle et al., (2012) PLoS One 8: e67780 
 
3.1 Introduction 
A SNP 35 kb upstream of HLA-C has been shown to be associated with differences in HIV-1 
viral set point (Fellay et al., 2007) - a key early determinant of the rate of HIV-1 disease 
progression. This SNP (-35T/C; rs9264942) also strongly associates with differences in HLA-C 
mRNA (Stranger et al., 2005; Fellay et al., 2007) and cell surface expression levels (Thomas et 
al., 2009). However, while these associations have consistently been shown in Caucasian 
cohorts (Fellay et al., 2007; Dalmasso et al., 2008; Fellay et al., 2009; Thomas et al., 2009; van 
Manen et al., 2009; Ballana et al., 2012), the association between the -35 SNP (rs9264942) and 
HIV-1 viral set point has not been shown to be significant in African American cohorts - despite 
the presence of this SNP in this population (Han et al., 2008; Shrestha et al., 2009; Apps et al., 
2013). This has lead to the suggestion that the -35 SNP is not the causative variant responsible 
for the alteration in HLA-C expression and viral set point, but rather acts as a marker in 
Caucasian populations for another functionally relevant polymorphism.  
 
This view is supported by the findings of Kulkarni et al. (2011), who identified a single base 
pair indel polymorphism at position 263 of the HLA-C 3' UTR that has been shown to be in LD 
with the -35 SNP in Caucasian individuals. They found that this variant (263 indel; rs67384697) 
affects the binding of a regulatory microRNA (miRNA148a) to the 3' UTR, with a deletion at 
this position (263del) abolishing miRNA148a binding and leading to increased HLA-C 
expression (Kulkarni et al., 2011; Kulkarni et al., 2013). They also found an over-representation 
of the 263del allele in HIV-1 controllers relative to non-controllers in a cohort of HIV-infected 
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individuals of European ancestry, suggesting that the change in HLA-C expression associated 
with this allele could help to provide long-term protection against HIV-1 disease progression 
(Kulkarni et al., 2011). However, these data are again only representative of individuals of 
Caucasian ancestry and have yet to be confirmed in other populations.  
 
That differences exist in patterns of genetic variation, and specifically in patterns of LD, 
between Black and Caucasian populations has become increasingly apparent. A recent study 
described HLA class I diversity in both Black and Caucasian South African populations 
(Paximadis et al., 2012) and outlined the patterns of LD that characterise this region, 
highlighting the key differences in HLA-C allelic representation between these two population 
groups.  However, no data are yet available regarding the -35 SNP or describing variation in the 
HLA-C 3' UTR in these populations. Here we report the first description of these data in 264 
unrelated South Africans from both the Black and Caucasian population groups.  
 
3.2 Materials and Methods 
3.2.1 Study Populations 
A total of 264 HIV-1 negative, unrelated South African individuals were used to describe 
genetic variation and patterns of LD within and between the coding and regulatory regions of 
the HLA-C locus. These 167 Black and 97 Caucasian South Africans were selected from a larger 
previously described cohort (Paximadis et al., 2012) on the basis of a non-reactive HIV ELISA 
test (Genscreen HIV1/2 version 2; Bio-Rad, Marnes-La-Coquette, France). Informed consent 
was obtained from all study participants and the study was approved by the University of the 
Witwatersrand Committee for Research on Human Subjects (Appendix B). 
 
The genomic DNA used for genotyping was extracted from buffy coat samples using the PEL-
FREEZ DNA Isolation Kit (DYNAL Invitrogen Corporation, Carlsbad, California, USA). 
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3.2.2 HLA-C Genotyping 
HLA-C genotyping was performed at both low and high resolution, using a combination of  
single specific primer-polymerase chain reaction (SSP-PCR) and sequence based typing (SBT) 
methods, as previously described (Paximadis et al., 2012). However, because the genotyping 
was performed prior to 2005, it was possible that alleles that had not yet been identified at the 
time of genotyping may have been present within the sample population. Misclassification of 
these alleles could potentially confound LD analyses. HLA-C*02:10 has previously been found 
at relatively high frequencies in other Black populations (Gonzalez-Galarza et al., 2011), 
however, it was not observed in the Black South African population during the prior genotyping 
(Paximadis et al., 2012). HLA-C*02:02 and HLA-C*02:10 differ by only a single amino acid 
(T211C) in exon 4 (Robinson et al., 2014), a difference that would not be detected by the SSP-
PCR genotyping kit previously employed to genotype these samples.  
 
Therefore, all Black individuals who had originally been typed as having HLA-C*02:02 alleles; 
as well as all individuals who were initially typed as homozygous at the HLA-C locus, were re-
genotyped using the AlleleSEQR HLA-C PLUS Sequence-Based Typing (SBT) Kit (Abbot 
Molecular, Des Plaines, Illinois, USA) according to the manufacturer's instructions. Sequencing 
analysis and allele assignment were performed using Assign™ SBT v3.5.1 software (Conexio 
Genomics, Fremantle, Western Australia, Australia), with the IMGT/HLA July 2011 (v3.6.0) 
references. Because at least one of the alleles in any genotype combination was already known 
(based on the previously available genotyping data), none of the retyped samples were regarded 
as ambiguous. 
3.2.3 HLA-C 3' UTR DNA Sequencing 
The HLA-C 3' UTR was amplified from genomic DNA using the PCR primers described by 
Kulkarni et al. (2011) and the following thermocycling conditions: 94°C for 2 minutes, 
followed by 30 cycles of 94°C for 15 seconds, 65°C for 30 seconds, 72°C for 90 seconds and 
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72°C for 7 minutes. The amplicons were sequenced in both directions by capillary 
electrophoresis using an ABI 3100 DNA analyzer (Applied Biosystems, Foster City, California, 
USA) and the sequencing primers: 5'-GTGAGATTCTGGGGAGCTGA-3' and 5'-
TCTGGAAGGTTCTCAGGTC-3'. The chromatograms obtained were analysed using 
Sequencher v4.2 (Genes Codes Corporation, Ann Arbor, Michigan, USA) and sequences were 
aligned with an available reference sequence (GenBank Accession Number NG_029422) to 
identify polymorphic positions.  
 
3.2.4 -35 SNP Genotyping 
A real-time PCR assay was designed to genotype the -35 SNP (rs9264942). PCR amplicons 
were amplified from genomic DNA using a common forward primer (5'-
GCCCATACCTGTTTATACATCCA-3') and one of two allele-specific reverse primers (5'-
CAGAAAGTCCCACAGTGCCTG-3' and 5'-CAGAAAGTCCCACAGTGCCTA-3'). Both 
allele-specific primers were designed with a lock nucleic acid (LNA) modified 3'-end base. The 
assay was performed using the Applied Biosystems 7500 Real-Time PCR system (Applied 
Biosystems, Foster City, California, USA) and the following thermocycling conditions: 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C for 15 seconds and 70°C 
for 1 minute. Reactions were performed in a 10 µl volume, containing 1x Maxima SYBR 
Green/ROX qPCR Master Mix (Fermentas, Burlington, Canada), 10 pmol of each primer and 
20-60 ng of DNA. PCR analysis was based on calculation of ∆CT (difference in cycle threshold; 
the difference between the CT of the -35T and -35C reactions). Heterozygous individuals had 
∆CT values of between 0 and 0.3, while homozygous TT and CC individuals had ∆CT values of 
≥4 or ≤-4, respectively. 
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3.2.5 Statistical Analyses 
Allele frequencies at all polymorphic positions were determined by direct counting. The 
significance of differences in allele frequency observed between the Black and Caucasian 
population groups were performed using a two-sided Fisher exact test (SISA: Simple Interactive 
Statistical Analysis). Deviations from Hardy-Weinberg equilibrium (HWE) were assessed using 
the Markov chain exact test for HWE (Guo and Thompson, 1992). The Excoffier-Laval-Balding 
(ELB) algorithm (Excoffier et al., 2003) was used to estimate the gametic phase of the 
genotypic data generated at all polymorphic positions, LD to be quantified as the LD 
coefficients D' (Lewontin, 1964) and r2 (Hill and Robertson, 1968). The significance of pairwise 
LD between all polymorphic positions was estimated using an exact test for LD (Slatkin, 1994). 
All HWE, LD and haplotypic analyses were implemented through Arlequin v3.5.1.2 (Excoffier 
and Lisher, 2010). All statistical measures were considered significant at p<0.05.  
 
3.3 Results 
3.3.1 Genetic Variation within the HLA-C 3’ UTR 
Direct sequencing of the 3’UTRs of the HLA-C alleles present in the Black and Caucasian South 
African population revealed this region contained 33 polymorphisms within the approximately 
400 bp of sequence analysed, including the indel at position 263 (Table 3.1). Thirty-one 
positions (including the 263 indel) were found to be polymorphic in both the Black and the 
Caucasian population groups, while positions 84 (84G/A; rs139211788) and 285 (285ACTT/-; 
rs60637457) were only polymorphic within the Black population. Minor allele frequencies 
differed significantly between the two population groups at 10 of these positions; however, 
these did not include the 263 indel (Table 3.1). Seven other SNPs previously reported in this 
region were not observed in either population. The Black population group deviated 
significantly from HWE at positions 46 (p = 0.026), 110 (p < 0.001), 138 (p = 0.001), 267 (p = 
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0.023) and 303 (p < 0.001), while positions 263 (p = 0.033), 266 (p = 0.032), 294 (p = 0.032), 
299 (p = 0.031), 300 (p = 0.032), 307 (p = 0.024), 345 (p = 0.032) and 346 (p = 0.032) deviated 
significantly from HWE in the Caucasian population group. 
 
A number of the polymorphisms present in the 3’ UTR were found to only be associated with 
specific HLA-C alleles (Figure 3.1). For the majority of alleles, these allele-specific 
polymorphisms were associated with the same HLA-C allele (or alleles) in both population 
groups (when the given HLA-C allele was present in both population groups). However, this 
was not the case for C*02:02 and C*02:05, which were found to be associated with different   
3’ UTR polymorphisms, depending on the population group under consideration. C*02:10 was 
also unique in that, unlike the other HLA-C alleles that were uniquely associated with either one 
263 indel variant or the other, this allele was found to associated with both the insertion and the 
deletion variants. This was also true for the indel at position 230 (Figure 3.1). 
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Table 3.1 The polymorphic positions present within the HLA-C 3’UTR and their minor 
allele frequencies within the Black and Caucasian population groups 
 
   Minor Allele Frequency  
Polymorphic NCBI Alleles Black Caucasian p-value2 
Position1 dbSNP ID  Individuals Individuals  
   (n = 167) (n = 96)  
46 rs1049853 C/T 0.067 0.089 - 
84 rs1049724 A/G 0.003 0.000 - 
92 rs1049709 A/G 0.052 0.177 <0.001 
93 rs1065711 C/T 0.061 0.151 0.001 
101 rs3176007 C/T 0.046 0.083 - 
110 rs41289069 C/T 0.135 0.047 0.001 
125 rs1049668 A/G 0.117 0.005 <0.001 
133 rs1049663 G/T 0.117 0.005 <0.001 
138 rs1049650 C/G 0.065 0.094 - 
146 rs116229144 C/T 0.117 0.005 <0.001 
179 rs1049579 C/T 0.117 0.005 <0.001 
224 rs1094 A/G 0.379 0.401 - 
230 rs35877659 G/- 0.379 0.401 - 
256 rs1130592 A/C 0.256 0.373 - 
259 rs3207555 C/T 0.307 0.260 - 
261 rs3207561 C/T 0.307 0.260 - 
263 rs67384697 G/- 0.354 0.313 - 
266 rs1130586 C/T 0.351 0.313 - 
267 rs1130580 A/G 0.253 0.286 - 
278 rs1130576 A/G 0.122 0.005 <0.001 
285 rs60637457 ACTT/- 0.003 0.000 - 
294 rs1130559 A/C 0.351 0.313 - 
299 rs1130558 A/G 0.351 0.313 - 
300 rs1130554 A/T 0.351 0.313 - 
303 rs1130552 A/G 0.065 0.135 0.006 
307 rs1071643 C/G/T 0.003 0.010 - 
324 rs1130538 G/T 0.393 0.401 - 
345 rs116302614 A/G 0.351 0.313 - 
346 rs115906458 A/G 0.351 0.313 - 
347 rs3189472 C/G 0.393 0.401 - 
356 rs115510686 A/G 0.122 0.005 <0.001 
375 rs114027487 C/T 0.074 0.078 - 
379 rs1049281 A/G 0.393 0.401 - 
 
1 Positions are given relative to the start of the HLA-C 3' UTR, as seen in Kulkarni et al. (2011). 
2 p-values are for a two-sided Fisher's exact test, only significant values (p < 0.05) are shown. 
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Figure 3.1: The association between the polymorphic variants observed within the HLA-C 3’ UTR and specific HLA-C alleles. Only alleles observed more than 
once in either population group have been included. The major and minor alleles at each polymorphic position are given, while the presence of the 
minor allele within a given HLA-C allele is indicated in blue. When both allelic variants have been observed to be associated with a particular HLA-
C allele, it is indicated in purple. At position 307, which is tri-allelic, the presence of the T allele has been indicated. The G allele at this position is 
uniquely associated with HLA-C*14:02. 
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3.3.2 Estimation of Haplotype Structure within the HLA-C 3’ UTR 
In order to further investigate the relationships between the genetic variants identified within the 
HLA-C 3’ UTR, the ELB algorithm (Excoffier et al., 2003) was used to estimate the gametic 
phase of the genotyping data generated at all the polymorphic positions within this region, 
allowing LD between these positions to be quantified. These LD analyses allowed for the 
identification of two overlapping haplotypes, involving multiple positions across the HLA-C    
3’ UTR. The larger of the haplotypes spanned across ten positions (263H - Figure 3.2a) and 
included the indel at position 263. The other extended across five positions (230H - Figure 3.2a) 
and encompassed the indel at position 230. Only positions with both D’ and r2 measures of 
pairwise LD equal to 1 were considered as these haplotypes. Both haplotypes were present at 
similar frequencies in both population groups. 
 
Because of strong linkage disequilibrium between the alleles at positions 230 and 263 (D’ = 1 
and r2 = 1, p < 0.001), the two haplotypes were only found to occur in three possible 
combinations (Figure 3.2b). The most commonly observed haplotypic combination in both 
groups was that of the 230H minor allele haplotype with the 263H major allele haplotype 
(230I/263I). Slightly less frequent in both population groups was the combination of the 230H 
major allele haplotype with the 263H minor allele haplotype (230D/263D). The combination of 
both major allele haplotypes (230D/263I) was the least common in both groups, while the 
combination of both minor allele haplotypes was never observed. The 230D/263D haplotype 
was found to occur at a slightly higher frequency in the Black population group, but this 
comparison did not reach statistical significance. 
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a. 
 
 
b. 
 
 
Figure 3.2: (a) The haplotypes occurring within the 3’ UTRs of the HLA-C alleles present in the Black and Caucasian South African population groups. The haplotypes 
were named 230H and 263H, for their association with the two indels present in the region. The major and minor alleles at each polymorphic position are 
indicated. (b). The combinations of the 230H and 263H haplotypes observed within the Black and Caucasian South African population groups. FB refers to 
the frequency of the given combination in the Black population group, while FC refers to the frequency within the Caucasian population group. The presence 
of the major allele at each polymorphic position is indicated in blue, while the presence of the minor allele is indicated in purple. 
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3.3.3 Linkage Disequilibrium between Specific HLA-C alleles and the -35 SNP  
A SNP 35 kb upstream of HLA-C has previously been shown to be associated with both HLA-C 
expression and HIV-1 viral set point (Stranger et al., 2005; Fellay et al., 2007; Thomas et al., 
2009). However, while repeatedly observed within Caucasian populations (Fellay et al., 2007; 
Dalmasso et al., 2008; Thomas et al., 2009; van Manen et al., 2009), this association has not 
been observed in populations of African descent (Han et al., 2008; Shrestha et al., 2009; Apps 
et al., 2013). We therefore examined genetic variability at the -35 SNP (rs9264942) and 
evaluated the extent of LD between this polymorphism and the HLA-C alleles present in the 
Black and Caucasian population groups (Table 3.2). 
 
The frequencies of the -35C allele in the Black (0.348) and Caucasian (0.284) population groups 
were not found to be significantly different (p = 0.13), and neither population group deviated 
significantly from HWE at this position. In the Black population group, the HLA-C alleles 
C*02:02, C*03:02, C*06:02, C*07:06, C*07:18, C*12:03 and C*14:02 were found to be in 
complete linkage with this allele, while C*03:04, C*04:01, C*17:01 and C*18:02 were in 
complete LD with the -35T allele. While not complete, C*02:10 (D’ = 0.59; p < 0.05), C*07:02 
(D’ = 0.86; p < 0.01) and C*16:01 (D’ = 0.76; p < 0.01) were also found to be in significant LD 
with the -35T allele. Of the 26 HLA-C alleles present in the Caucasian population, 15 were 
found to be in significant LD with the -35 SNP (Table 3.2). C*02:02, C*06:02, C*07:06, 
C*07:18, C*08:04, C*12:02, C*12:03 and C*14:02 were in complete linkage with the -35C 
allele, while C*03:03, C*03:04, C*04:01, C*07:01, C*07:02 and C*16:01 were in complete 
LD with the -35T allele. Although not complete, C*01:02 was also found to be in significant 
LD with the -35C allele (D' = 0.65, p < 0.05).  
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Table 3.2 Linkage disequilibrium between the -35 SNP (rs9624942) and the HLA-C 
alleles present in the Black and Caucasian South African population groups 
 
 
HLA-C 
Allele 
Black Individuals 
(n = 168) 
Caucasian Individuals 
(n = 97) 
Allele Frequency D’ p-value1 Allele Frequency D’ p-value1 
01:02 - - - - C 0.0155 (3) 0.65 <0.05 
02:02 C 0.0149 (55) 1.00 <0.05 C 0.0723 (14) 1.00 <0.01 
02:05 T 0.0030 (1) 1.00 NS C 0.0052 (1) 1.00 NS 
02:10 T 0.0655 (22) 0.59 <0.05 - - - - 
03:02 C 0.0149 (5) 1.00 <0.01 - - - - 
03:03 C 0.0030 (1) 1.00 NS T 0.0619 (12) 1.00 <0.05 
03:04 T 0.0446 (15) 1.00 <0.01 T 0.0567 (11) 1.00 <0.05 
03:16 - - - - T 0.0052 (1) 1.00 NS 
04:01 T 0.1250 (42) 1.00 <0.01 T 0.0876 (17) 1.00 <0.01 
04:04 T 0.0030 (1) 1.00 NS - - - - 
04:08 - - - - T 0.0052 (1) 1.00 NS 
05:01 C 0.0060 (2) 0.49 NS T 0.0412 (8) 0.28 NS 
06:02 C 0.1488 (50) 1.00 <0.01 C 0.0773 (15) 1.00 <0.01 
06:06 C 0.0030 (1) 1.00 NS - - - - 
06:11 C 0.0030 (1) 1.00 NS C 0.0052 (1) 1.00 NS 
07:01 T 0.0506 (17) 0.16 NS T 0.1753 (34) 1.00 <0.01 
07:02 T 0.0595 (20) 0.86 <0.01 T 0.1443 (28) 1.00 <0.01 
07:04 T 0.0149 (5) 1.00 NS T 0.0103 (2) 1.00 NS 
07:06 C 0.0387 (13) 1.00 <0.01 C 0.0206 (4) 1.00 <0.01 
07:11 T 0.0030 (1) 1.00 NS - - - - 
07:18 C 0.0417 (14) 0.89 <0.01 C 0.0155 (3) 1.00 <0.01 
08:01 T 0.0030 (1) 1.00 NS T 0.0052 (1) 1.00 NS 
08:02 T 0.0119 (4) 0.42 NS C 0.0103 (2) 0.31 NS 
08:04 C 0.0149 (5) 0.24 NS C 0.0103 (2) 1.00 <0.05 
12:02 - - - - C 0.0103 (2) 1.00 <0.05 
12:03 C 0.0149 (5) 1.00 <0.01 C 0.0206 (4) 1.00 <0.01 
14:02 C 0.0060 (2) 1.00 <0.05 C 0.0103 (2) 1.00 <0.05 
15:02 T 0.0060 (2) 1.00 NS T 0.0258 (5) 1.00 NS 
15:05 T 0.0089 (3) 1.00 NS - - - - 
16:01 T 0.0655 (22) 0.76 <0.01 T 0.0670 (13) 1.00 <0.05 
16:02 - - - - T 0.0103 (2) 1.00 NS 
17:01 T 0.1131 (38) 1.00 <0.01 T 0.0052 (1) 1.00 NS 
18:01 T 0.0149 (5) 1.00 NS - - - - 
18:02 T 0.0298 (10) 1.00 <0.05 - - - - 
 
               1 P-values are for an exact test for linkage disequilibrium (Slatkin, 1994) and are significant at p < 0.05. 
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3.3.4 Linkage Disequilibrium between the -35 SNP and the 263 Indel 
It has been suggested that the association observed between the -35 SNP and HLA-C expression 
observed in populations of European descent is due strong LD between this SNP and the indel 
at position 263 of the HLA-C 3’ UTR (Kulkarni et al., 2011). We therefore evaluated the extent 
of LD between these two polymorphisms in the Black and Caucasian South African population 
groups and found that in contrast to previous observations in other Caucasian populations (D’ = 
0.75; Kulkarni et al., 2011), the -35 SNP was found to be only weakly associated with the 263 
indel in both the Black (D' = 0.46; p < 0.001) and the Caucasian (D' = 0.34; p < 0.001) 
population groups. In both groups, the -35C allele was associated with 263del and the -35T 
allele with 263ins.  
 
3.4 Discussion 
We examined genetic variation within the 3' UTRs of the HLA-C alleles present in the Black 
and Caucasian South African population groups and investigated the relationship between these 
variants and a SNP 35 kb upstream of the HLA-C locus. The data confirmed the presence of the 
263 indel (rs67384697) in both population groups, as well as that of other polymorphisms 
previously identified within this region in other populations (Xu et al., 2011;  Kulkarni et al., 
2011; O’hUigin et al., 2011). The persistence of strong LD was observed between particular     
3' UTR polymorphisms in both population groups and the underlying haplotypic structure of the 
region was described. Finally, these data demonstrated that the -35 SNP (rs9624942) is not in 
strong LD with the 263 indel in either the Black or the Caucasian South African population; and 
as such, is not an appropriate marker for this indel in either of these groups.  
 
Previous investigations of genetic variability within the HLA-C 3' UTR in other populations 
have identified numerous polymorphisms other than the 263 indel in this region (Xu et al., 
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2011; Kulkarni et al., 2011; O’hUigin et al., 2011). Consistent with their findings, our analysis 
of the same region identified 33 of these polymorphisms in the Black South African population. 
The variation identified within the Caucasian South African population represented only a 
subset of that seen in the Black population group. However, the additional polymorphisms 
observed in the Black population group were not unique to this population, having been 
previously described in other studies (Xu et al., 2011; Kulkarni et al., 2011; O’hUigin et al., 
2011). A number of these polymorphisms were found to deviate from HWE in both population 
groups - although different polymorphisms were seen to deviate from HWE between the Black 
and Caucasian population groups. While deviation from HWE can often be attributed to 
genotyping errors, this is unlikely to be the case in this instance, as all genotyping was 
performed by direct sequencing. In light of the finding that a subset of these polymorphisms are 
unique to specific HLA-C alleles and given the differences observed in the HLA-C allele 
distributions between the two population groups, these deviations from HWE most likely reflect 
the influence of  random genetic drift. 
 
As previously observed (Xu et al., 2011; Kulkarni et al., 2011; O’hUigin et al., 2011), the 
majority HLA-C alleles observed within the Caucasian population group were represented by a 
single, distinctive 3' UTR sequence. However, contrary to prior observations, several different 
sequences were observed for the C*02:02 allele in this population group – none of which 
corresponded to the sequence previously reported for this allele. Nonetheless, despite this 
variability, none of the 3’ UTR sequences observed for C*02:02 differed with respect to their 
263 indel allele. A similar pattern was observed for the 3’ UTR sequences of the HLA-C alleles 
present in the Black population group – with C*02:02 again showing a high degree of 
variability within this population group, but without differing with respect to the 263 indel allele 
observed. However, one allele present only in the Black population group (HLA C*02:10), was 
found to be associated with both the insertion and the deletion at position 263. Coupled with 
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the finding that the 3’ UTR sequence observed for C*02:05 differed between the two population 
groups, these data may suggest that a diversity of genetic variability exists within the HLA   
Cw 02 alleles that cannot be adequately described using the current commonly used HLA-C 
SBT genotyping methods.    
 
LD analysis between all the polymorphisms present in the HLA-C 3’ UTR revealed the 263 
indel to be at the centre of a large haplotype involving the same ten polymorphic positions in 
both the Black and Caucasian populations. This indel is thought to regulate differential HLA-C 
expression by disrupting a putative miRNA binding site (Kulkarni et al., 2011; Kulkarni et al., 
2013). It has previously been shown to be in complete linkage with the SNPs at positions 256, 
261 and 266; and as none of these SNPs produced any significant change in luciferase activity 
when analysed independently, the indel is thought to be responsible for any differences seen in 
HLA-C expression (Kulkarni et al., 2011). However, all analyses of alterations in luciferase 
activity involving the indel included concomitant modifications at all four positions, and all four 
polymorphisms occur within the putative miR-148a/miR-148b binding site (Kulkarni et al., 
2011), allowing for the possibility that concomitant changes at these positions may act 
synergistically to disrupt miRNA binding.  
 
Similarly, the SNP at position 307 was also previously shown to be potentially disruptive of a 
putative miRNA binding site, but when analysed independently did not produce any significant 
changes in luciferase activity (Kulkarni et al., 2011). However, if analysed in haplotypic 
combination with the SNPs at positions 299, 300 and 303, which occur within the same putative 
mi-657 binding site (Kulkarni et al., 2011); a significant difference in expression may 
potentially be observed, as the presence of multiple mismatched bases within the same binding 
site would most likely increase the probability of disruption of miRNA binding relative to 
modification at a single position. Additionally, the observation that these variants always occur 
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in combination with each other, and could thus collectively potentially prevent binding of more 
than one miRNA, would further suggest that the presence of the haplotype (rather than any one 
single polymorphism) is responsible for the differential expression of HLA-C alleles observed. 
However, further functional studies would be required to test this hypothesis. 
 
A second large haplotype encompassing the indel at position 230 and four other SNPs was also 
observed in both populations. The presence of an insertion at position 230, coupled with a 
guanine at 224, introduces at additional putative miR-181a binding site into the HLA-C 3' UTR 
(Kulkarni et al., 2011). Because of strong LD between the two indels, these haplotypes occur in 
three overlapping configurations within all the HLA-C alleles observed within the Black and 
Caucasian South African population groups, each of which is potentially subject to differential 
degrees of miRNA-mediated gene regulation. HLA-C 3' UTR sequences with deletions at both 
positions 230 and 263 would therefore potentially disrupt the binding of four miRNAs (miR-
181a, miR-148a/miR-148b, miR-657 and miR-181a*; Kulkarni et al., 2011), while those 
sequences with insertions would be inhibited at the same positions. Sequences with a deletion at 
position 230 and insertion at 263 would disrupt two putative miRNA binding sites (miR-
148a/miR-148b and miR-657; Kulkarni et al., 2011), and thus potentially exhibit a phenotype of 
intermediate expression. The presence of these alternative haplotype combinations could thus 
account for the variances previously observed in HLA-C expression (Thomas et al., 2009; 
Corrah et al., 2011; Kulkarni et al., 2011). Again, however, further functional studies are 
necessary to test this hypothesis. 
 
The suggestion that the overlap of the two haplotypes described could potentially account for 
observed variances in HLA-C expression is consistent with the previous findings of Corrah et 
al. (2011), who prior to the identification of the 263 indel, used monoclonal antibodies to 
examine HLA-C expression in relation to -35 SNP genotype (Corrah et al., 2011). They 
attributed the association between the -35T allele and higher HIV-1 viral set point observed in 
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Caucasian individuals (Fellay et al., 2007; Dalmasso et al., 2008; Fellay et al., 2009; Thomas et 
al., 2009; van Manen et al., 2009) to the especially low expression of HLA-Cw*07 alleles, 
which are particularly common in individuals of European descent (Gonzalez-Galarza et al., 
2011). This association is not seen in African-American populations (Han et al., 2008; Shrestha 
et al., 2009), where HLA-Cw*07 is less prevalent. All the HLA-Cw*07 sequences analysed 
during the course of our investigation had insertions at both indel positions, and would thus 
(under the aforementioned model) be subject to especially strong miRNA-mediated inhibition. 
This could also partially account for variances in the distribution of HLA-C expression levels 
observed in other functional studies (Kulkarni et al., 2011;  Apps et al., 2013). 
 
This association between the -35 SNP and HLA-C expression (Thomas et al., 2009), was 
previously thought to be responsible for the differences in HIV-1 viral set point observed in 
Caucasian individuals. However, the 263 indel is now considered to be the actual variant 
responsible for the differential regulation of HLA-C expression, which, in turn, is thought to be 
responsible for the variation seen in HIV-1 viral set point (Kulkarni et al., 2011). The 
association observed between the -35 SNP and in HIV-1 viral set point has since been attributed 
to strong LD between the SNP and indel (Kulkarni et al., 2011).   
 
Examination of the extent of LD between the -35 SNP and 263 indel in both the Black and 
Caucasian populations revealed LD between them (and all the other SNPs in the haplotype) to 
be weak in both groups. However when linkage between the -35 SNP and specific HLA-C 
alleles was examined, LD was found to be complete and significant for fourteen alleles in the 
Caucasian population. This was consistent with previous reports in other Caucasian populations 
(Thomas et al., 2009; Kulkarni et al., 2011). LD was not found to be significant for more than 
50% of the HLA-C alleles in the Black population group. This is consistent with observations in 
African-American populations, where common HLA-C alleles show no significant LD with the  
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-35 SNP and for alleles that do show significant LD, linkage is not complete (The International 
HIV Controllers Study et al., 2010). 
 
Thus while the -35 SNP may be indicative of specific HLA-C alleles in the Caucasian 
population, it cannot be regarded as an effective marker for the 263 indel in either the Black or 
Caucasian South African population groups. The -35 SNP was also not in strong LD with the 
230 indel in either population group (data not shown). Thus, as has been shown in the African-
American population (The International HIV Controllers Study et al., 2010), this SNP is 
unlikely to associate with either HLA-C expression or HIV-1 viral set point in these groups. 
However, this is yet to be confirmed. Whether the -35 SNP associates with any other as yet 
unidentified polymorphisms that influence HIV-1 disease progression by alternative 
mechanisms may warrant further investigation. 
 
In conclusion, these data provide the first description of variation in the regulatory regions of 
HLA-C for the Black and Caucasian South African populations. Furthermore, the data from the 
Black population are the first for a sub-Saharan African population. These data allow for a 
description of the haplotypic patterns within the HLA-C 3' UTR and identify two overlapping 
haplotypes within this region - which we hypothesize may act independently and synergistically 
to influence miRNA regulation of HLA-C expression. Concomitantly, we demonstrate that the  
-35 SNP is not in strong LD with either haplotype (in either population) and as such is unlikely 
to be an appropriate marker for HLA-C expression in either of these populations. Even in the 
absence of supporting expression data, these findings provide important insights into genetic 
variability within the regulatory regions of HLA-C, that have potential implications for our 
understanding of the regulation of HLA-C expression and its impact on HIV-1 disease 
progression in the populations occupying the region worst affected by this epidemic. 
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Chapter 4 
Genetic Variability at Residues within HLA-A and HLA-B 
that Determine Peptide Specificity are Associated with HIV-1 
Control in Black South Africans 
 
4.1 Introduction 
The rate of HIV-1 disease progression is known to be highly variable between individuals. A 
small subset of HIV-1 infected individuals, termed HIV-1 controllers, are able to spontaneously 
suppress viral replication and maintain very low levels of viraemia (< 2000 RNA copies/ml) in 
the absence of highly active antiretroviral therapy. Genetic variability within the HLA gene 
complex is well established as one of the major determinants of HIV-1 control (Fellay et al., 
2007; The International HIV Controllers Study et al., 2010), with associations between specific 
HLA class I alleles and haplotypes (Goulder and Walker, 2012), as well as variation within non-
coding regulatory regions (Fellay et al., 2007; Dalmasso et al., 2008; Kulkarni et al., 2011; 
Ballana et al., 2012) and HIV-1 control having been well documented.  
 
Recently, association testing of individual polymorphic amino acids within the classical HLA 
class I loci has also identified key residues, located predominantly within the peptide binding 
groove, that are strongly associated with HIV-1 control (The International HIV Controllers 
Study et al., 2010; McLaren et al., 2012). However, because ethnically and geographically 
distinct populations often display marked differences in their HLA allele frequency spectrums 
and the patterns of LD they exhibit across the HLA gene complex, associations observed at 
these loci may not always be consistently replicable in all population groups (Fellay et al., 2007; 
Shrestha et al., 2009; van Manen et al., 2009; The International HIV Controllers Study et al., 
2010; McLaren et al., 2012).  
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Associations between specific HLA class I alleles and HIV-1 control have been well 
documented within the Black South African population (Kiepiela et al., 2004; Honeyborne et 
al., 2007; Leslie et al., 2010). However, the impact of genetic variability at individual amino 
acids within HLA class I loci, as well as at positions outside of the protein coding region, on 
HIV-1 control have yet to be assessed in this population. We therefore examined patterns of 
genetic variability within and across the HLA-A, -B and -C loci in 111 treatment-naïve HIV-1 
infected Black South Africans exhibiting differing degrees of viral control.  
 
Our results demonstrate that genetic variability at specific residues within the HLA-A and –B 
peptide binding grooves is strongly associated with HIV-1 control in this population group. In 
accordance with previous reports (The International HIV Controllers Study et al., 2010; 
McLaren et al., 2012), this association is not seen for the corresponding residues within HLA-C. 
In addition, we further show that, as seen in African-Americans (McLaren et al., 2012), genetic 
variability within the HLA-C 3’UTR, thought to influence HLA-C expression (Kulkarni et al., 
2011; Kulkarni et al., 2013) is not significantly associated with HIV-1 control in the Black 
South African population. 
 
4.2 Materials and Methods 
4.2.1 Study Populations 
A total of 111 treatment-naïve HIV-1 infected Black South Africans were included in this study 
in order to investigate the impact of genetic variability within the HLA gene complex on HIV-1 
control. Sixty-nine of these individuals were classified as HIV-1 progressors based on a CD4+ T 
cell count that declined to below 300 cells/mm3 prior to the administration of antiretroviral 
(ART) therapy. As decisions to commence ART are based solely on CD4+ T cell count, which 
may then include HIV-1 controllers with declining counts, we included the criterion of high 
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viraemia (i.e. viral loads greater than 10 000 RNA copies/ml) to identify progressors (Table 
4.1). The remaining 42 HIV-1 positive individuals were classified as HIV-1 controllers on the 
basis of their having CD4+ T counts greater than 300 cells/mm3, while also suppressing viral 
replication to levels below 2000 RNA copies/ml. 
 
Table 4.1 A summary of the clinical characteristics used to classify individuals as either 
HIV-1 progressors or -controllers 
 
 
CD4+ T Cell Count  
(cells/mm3) 
Log Viral Load  
(RNA copies/ml) 
Median Range Median Range 
HIV-1 Progressors 
(n = 69) 178 3 - 296 4.57 4.01 - 5.70 
HIV-1 Controllers 
(n = 42) 699 306 - 1380 2.54 1.7 - 3.24 
 
 
HIV-1 RNA levels were quantitated using either the Roche Amplicor RNA Monitor assay 
(lower detection limit of 400 HIV-1 RNA copies/ml) or, where necessary, the COBAS 
AmpliPrep/COBAS Taqman HIV-1 Test, v2.0 (Roche Molecular Diagnostics, Pleasanton, 
California, USA), which has a lower detection limit of 50 RNA copies/ml. CD4+ T cell counts 
were determined using the FACSCount System (BD Biosciences, San Jose, California, USA). 
Informed consent was obtained from all study participants and the study was approved by the 
University of the Witwatersrand Committee for Research on Human Subjects (Appendix B). 
 
4.2.2 DNA Extraction 
The DNA obtained from HIV-1 controllers was extracted from whole blood samples, while that 
obtained from HIV-1 progressors was derived from frozen buffy coat samples. All DNA 
extractions were performed by silica spin-column purification using the QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany).  
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4.2.3 HLA Class I Genotyping 
HLA class I genotyping was performed at high resolution for the HIV-1 controllers included in 
this study using the AlleleSEQR HLA-A, HLA-B and HLA-C PLUS SBT kits (Abbot Molecular, 
Des Plaines, Illinois, USA). This SBT method involved initial amplification of a 2 kb fragment 
of the gene, followed by bidirectional direct sequencing of exons 2, 3 and 4 by capillary 
electrophoresis using the ABI 3100 DNA analyzer (Applied Biosystems, Foster City, 
California, USA). Allele assignment was performed using Assign™ SBT v3.5.1 (Conexio 
Genomics, Fremantle, Western Australia, Australia), based on the IMGT/HLA July 2014 
(v3.17.0) references.  
 
The HLA class I genotyping for the 69 HIV-1 progressors was performed by next-generation 
sequencing (NGS) using the GS FLX System (454 Life Sciences, Branford, Connecticut, USA). 
This system involves multiplexed, clonal, amplicon-based pyrosequencing of exons 2 and 3 of 
all three HLA class I loci, using a combination of multiple locus-specific primers, each with 
unique multiplex identifiers (MIDs). Allele assignment was carried out using IIID Allele Caller, 
in-house software designed and used by the Institute for Immunology and Infectious Diseases at 
Murdoch University, Murdoch, Western Australia, Australia. 
 
4.2.4 Resolution of HLA Ambiguity 
The allele assignment algorithms employed during HLA class I genotyping assign individual 
genotypes based on the nucleotide sequences observed at specific key positions within exons 2, 
3 and 4 of each gene. However, the presence of specific heterozygous combinations at these 
positions can often lead to ambiguity in the genotype assignment. This is particularly 
problematic in (the not uncommon) instances where two or more HLA alleles have identical 
sequences at these positions (Robinson et al., 2014). While these ambiguities can be resolved 
experimentally (Paximadis et al., 2012), the high costs and time consuming nature of HLA class 
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I genotyping make it more prudent to find alternative algorithmic solutions to this problem 
(Nunes et al., 2014). 
 
Therefore, in the case of the 111 treatment-naïve HIV-1 infected Black South Africans included 
in this study, genotypic ambiguities were not resolved experimentally. Rather - given the high 
levels of LD observed across the MHC region and increased likelihood of observing common 
alleles at these loci - where ambiguities were observed, individuals were assigned the genotype 
regarded as being the most likely given the population-specific allele frequencies and patterns of 
LD previously observed across these loci by Paximadis et al. (2012) and others (Gonzalez-
Galarza et al., 2011). In the case of the HLA-C locus, where necessary, additional data regarding 
allele-specific polymorphic variants within the HLA-C 3’ UTR were included in allele 
assignment.  
 
4.2.5 Evaluation of the Polymorphic Positions within HLA Class I Loci 
SNPs within exons 2, 3 and 4 of each the three HLA class I loci were identified following 
multiple sequence alignment of the sequence data obtained from HLA allele typing with the 
appropriate available reference sequences (GenBank Accession Numbers NM_001242758, 
NM_005514 and NM_002117). The amino acid residues corresponding to all non-synonymous 
positions were determined based on the sequence information available within the IMGT/HLA 
database (Robinson et al., 2014). 
 
4.2.6 HLA-C 3' UTR DNA Sequencing  
The HLA-C 3' UTR was amplified from genomic DNA using the PCR primers described by 
Kulkarni et al. (2011), as previously described (Chapter 3; Section 3.2.3).  Bi-directional 
sequencing of the resulting amplicons was performed by capillary electrophoresis using an ABI 
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3100 DNA analyzer (Applied Biosystems, Foster City, California, USA). All sequence analysis 
was performed using Sequencher v4.2 (Genes Codes Corporation, Ann Arbor, Michigan, USA) 
and sequences were aligned with an available reference sequence (GenBank Accession Number 
NG_029422) to identify polymorphic positions.  
 
4.2.7 Statistical Analyses 
HLA class I allele and SNP frequencies were determined by direct counting. The association 
between specific HLA class I alleles and HIV-1 control was evaluated using multivariate logistic 
regression, as implemented in R v3.1.1 (www.r-project.org). The significance of differences in 
the allele frequencies at individual polymorphic positions within HLA loci between HIV-1 
progressors and -controllers was assessed using the Fisher’s exact test implemented in PLINK 
v1.07 (Purcell et al., 2007). HLA class I allelic haplotypes were estimated using Arlequin 
v3.5.1.2 (Excoffier and Lisher, 2010), while individual SNP haplotypes were identified using 
PLINK v1.07 (Purcell et al., 2007). The significance of allele and genotype frequency 
differences observed between HIV-1 progressors and –controllers at polymorphic positions 
within the HLA-C 3’ UTR was also assessed using a two-sided Fisher’s exact test, as 
implemented in R v3.1.1 (www.r-project.org). All statistical measures were considered 
significant at p < 0.05.  
 
4.3 Results 
4.3.1 Association of specific HLA Class I alleles with HIV-1 Control 
We evaluated the association of HLA class I alleles with HIV-1 control in Black South African 
HIV-1 progressors and controllers and found four alleles to be significantly associated with 
differential HIV-1 control (Table 4.2). Consistent with previous studies conducted within the 
Black South African population (Kiepiela et al., 2004; Leslie et al., 2010; Tang et al., 2011) and 
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others (Lazaryan et al., 2006; Lazaryan et al., 2010; McLaren et al., 2012), B*57:03:01, 
B*58:01:01 and B*39:10:01 were identified as the alleles most strongly associated with HIV-1 
control. A*03:01:01 has also previously been shown to be associated with reduced absolute 
CD4+ T cell count in Black South Africans (Leslie et al., 2010). An association was not seen for 
any individual HLA-C alleles, however the association observed for B*39:10:01 was only seen 
when found in haplotypic combination with C*12:03:01; while the B*81:01:01|C*04:01:01 
haplotype was found to be associated with HIV-1 control (p = 0.020, OR = ∞), despite no 
association being seen for either individual allele. These results were again consistent with 
previous observations within the Black South African population (Leslie et al., 2010). 
 
Table 4.2 HLA class I alleles associated with differential HIV-1 control 
 
HLA Allele 
HIV-1 
Progressors 
(n = 69) 
HIV-1 
Controllers 
(n = 42)1 
OR (95% 
Confidence 
Interval)2 
p-value2 
 
n Frequency n Frequency 
B*57:03:01 3 0.022 5 0.060 13.7 (1.5 - 159.3) 0.024 
B*58:01:01 4 0.029 6 0.071 9.8 (1.3 - 99.5) 0.037 
B*14:02:01 2 0.014 3 0.036 9.0 (0.8 - 13.3) 0.080 
B*39:10:01 4 0.029 5 0.060 8.5 (1.2 - 70.3) 0.037 
B*14:01:01 2 0.014 3 0.036 7.0 (0.7 - 8.5) 0.098 
B*42:01:01 9 0.065 9 0.107 4.6 (0.9 - 28.4) 0.080 
A*23:01:01 14 0.101 4 0.059 0.1 (0.0 - 1.0) 0.066 
A*03:01:01 11 0.080 1 0.015 0.0 (0.0 - 0.3) 0.012 
 
 
                      1 Only 34 HIV-1 controllers were genotyped at the HLA-A locus. 
                       2 Odds ratios and p-values based on multivariate logistic regression, as implemented in R v 3.1.1  
                 (www.r-project.org). 
 
4.3.2 Association of Polymorphic Positions within the HLA Class I Peptide-
binding Groove with HIV-1 Control 
The allele frequencies of the individual polymorphic positions within the HLA class I loci were 
compared between HIV-1 progressors and –controllers, in order to assess their potential 
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association with HIV-1 control. Only variants within exons 2, 3 and 4 were considered, as these 
were the exons for which sequencing data were available. In addition, as the functional 
implications of genetic variability within these exons were anticipated to arise as a consequence 
of alterations in the resulting protein structure, only non-synonymous polymorphisms were 
considered – reducing the number of SNPs under consideration to 58 in HLA-A, 47 in HLA-B 
and 43 in HLA-C. 
 
Table 4.3 The polymorphic positions within the HLA-A locus associated with differential 
HIV-1 control 
 
Position 
 
Amino 
Acid 
HIV-1 
Progressors 
(n = 69) 
HIV-1 
Controllers 
(n = 34) 
OR (95% 
Confidence 
Interval)1 
p-value2 
 
17 S 0.167 0.324 2.4 (1.2 - 4.7) 0.013 
56 R 0.167 0.324 2.4 (1.2 - 4.7) 0.013 
97 M 0.355 0.191 0.4 (0.2 - 0.9) 0.016 
114 E 0.167 0.324 2.4 (1.2 - 4.7) 0.013 
116 H 0.167 0.324 2.4 (1.2 - 4.7) 0.013 
144 K 0.486 0.324 0.5 (0.3 - 0.9) 0.036 
149 T 0.065 0.162 2.8 (1.1 - 7.0) 0.042 
152 V 0.688 0.515 0.4 (0.3 - 0.9) 0.021 
 
1 Odds ratio 
2 p-values are for a two-sided Fisher’s exact test, as implemented in R v3.1.1 (www.r-project.org). 
 
Eight SNPs within HLA-A were found to be present at significantly different frequencies in 
HIV-1 progressors and –controllers (Table 4.3), four of which (positions 17, 56, 114 and 116) 
were found to be in complete LD (r2 = 1; p < 0.001). The Ser17-Arg56-Glu114-His116 haplotype 
was significantly associated with HIV-1 control (p = 0.013; OR = 2.4) and was found to be 
unique to HLA-A*30 alleles (A*30:01:01, A*30:02:01, A*30:04:01 and A*30:09; Figure 4.1). 
An independent association with HIV-1 control was observed at position 149, while variability 
at positions 97, 144 and 152 was associated with loss of control (Table 4.3). 
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Figure 4.1: The relationship between individual polymorphisms within HLA-A associated with 
differential HIV-1 control and specific HLA-A alleles. Positions favourably associated 
with HIV-1 control are shaded in green, while those associated with loss of control are 
shaded in red. Only the HLA-A alleles present in HIV-1 progressors and –controllers are 
represented. 
 
Twelve SNPs within HLA-B were found to be present at significantly different frequencies in 
HIV-1 progressors and –controllers (Table 4.4). However, due to strong LD between these 
variants only a limited number of independent associations with differential HIV-1 control were 
observed. Alleles at position 70 were found to be in strong LD with those at positions 69 and 
71, positions 24 and 41 were seen to be in strong LD with position 67, and alleles at position 32 
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were strongly associated with those at position 45. Consistent with previous reports (The 
International HIV Controllers Study et al., 2010; McLaren et al., 2012), Val97 - unique to HLA-
B*57 alleles (Figure 4.2) – was most strongly associated with HIV-1 control (p = 0.026; OR = 
4.7). The Ala69-Gln70-Ala71 and Ala69-Ser70-Ala71 haplotypes were also seen to be associated 
with HIV-1 control, while variants at positions 9, 24, 32, 41, 45, 67, 116 and 167 were 
associated with loss of control. Despite strong LD between the variants identified within both 
HLA-A and –B, significant LD was not observed between these variants across loci (data not 
shown). 
 
Table 4.4 The polymorphic positions within the HLA-B locus associated with differential 
HIV-1 control 
 
Position 
 
Amino 
Acid 
HIV-1 
Progressors 
(n = 69) 
HIV-1 
Controllers 
(n = 42) 
OR (95% 
Confidence 
Interval)1 
p-value2 
 
9 Y 0.790 0.558 2.9 (1.2 - 8.3) 0.014 
24 T 0.246 0.058 0.3 (0.1 - 0.7) 0.005 
32 L 0.210 0.095 0.4 (0.2 - 0.9) 0.027 
41 T 0.246 0.058 0.3 (0.1 - 0.7) 0.005 
45 K 0.210 0.095 0.4 (0.2 - 0.9) 0.027 
67 S 0.384 0.138 0.5 (0.2 - 0.9) 0.018 
69 A 0.333 0.488 1.9 (1.1 - 3.3) 0.024 
70 N 0.667 0.312 0.5 (0.3 - 0.9) 0.024 
71 A 0.333 0.488 1.9 (1.1 - 3.3) 0.024 
97 V 0.022 0.058 4.7 (1.1 - 28.3) 0.026 
116 L 0.145 0.022 0.2 (0.4 - 0.8) 0.011 
167 S 0.210 0.095 0.4 (0.2 - 0.9) 0.027 
 
1 Odds ratio 
2 p-values are for a two-sided Fisher’s exact test, as implemented in R v3.1.1 (www.r-project.org). 
 
No associations were observed at polymorphic positions within HLA-C, again consistent with 
previous studies that found genetic variation outside the peptide-binding domain of this locus to 
be associated with HIV-1 control (The International HIV Controllers Study et al., 2010; 
McLaren et al., 2012). 
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Figure 4.2: The relationship between individual polymorphisms within HLA-B associated with 
differential HIV-1 control and specific HLA-B alleles. Positions favourably associated 
with HIV-1 control are shaded in green, while those associated with loss of control are 
shaded in red. Only the HLA-B alleles present in HIV-1 progressors and –controllers are 
represented. 
 
 
  
68
4.3.3 Association of Polymorphic Positions within the HLA-C 3’ UTR with HIV-1 
Control 
Allelic variability at an indel polymorphism at position 263 (rs67384697) within the HLA-C 3’ 
UTR has previously been shown to be associated with HIV-1 control (Kulkarni et al., 2011). 
The presence of a deletion at this position is associated with increased HLA-C expression, due 
to disruption of an miRNA binding site (Kulkarni et al., 2011; Kulkarni et al., 2013), and 
increased HLA-C expression has been shown to be associated with HIV-1 viral control (Apps et 
al., 2013). We therefore, examined the association between genetic variability at this position 
(rs67384697) and HIV-1 control in the Black South African population, but found no difference 
in the frequency distribution of the protective 263D allele between HIV-1 progressors and –
controllers (Table 4.5). 
 
We have previously reported that the 263 indel is in strong LD with another indel at position 
230 of the HLA-C 3’ UTR (rs35877659) in the Black South African population (Chapter 3). 
Due to the haplotypic structure present within the HLA-C 3’ UTR, we hypothesized that genetic 
variability at this position may have the potential to impact HLA-C expression (and thus HIV-1 
control) in a manner similar to that seen at position 263 (Chapter 3). Examination of genetic 
variability at this position within HIV-1 progressors and –controllers revealed that while 
possession of a deletion at position 230 was not found to be significantly associated with HIV-1 
control in the Black South Africa, HIV-1 controllers were considerably less likely than 
progressors to possess two copies of the potentially deleterious 230I allele at this position 
(Table 4.5).  
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Table 4.5 The proportion of HIV-1 progressors and –controllers in possession of specific 230 (rs35877659) and 263 (rs67384697) indel alleles 
and genotypes 
 
 
230 Indel 263 Indel 
I D II ID DD I D II ID DD 
HIV-1 
Progressors 
(n = 62) 
 
HIV-1 
Controllers 
(n = 37) 
0.468 
 
 
0.405 
 
0.806 
 
 
0.919 
 
0.210 
 
 
0.081 
 
0.258 
 
 
0.324 
 
0.548 
 
 
0.595 
 
0.758 
 
 
0.730 
 
0.565 
 
 
0.595 
 
0.435 
 
 
0.405 
 
0.323 
 
 
0.324 
 
0.242 
 
 
0.270 
 
OR  
(95% CI)1 
0.8  
(0.3 - 1.9) 
2.7  
(0.7 - 16.0) 
0.3  
(0.1 - 1.4) 
1.4  
(0.5 - 3.7) 
1.2  
(0.5 - 3.0) 
0.9  
(0.3 - 2.5) 
1.1  
(0.5 - 2.8) 
0.9  
(0.4 - 2.2) - 
1.2  
(0.4 - 3.2) 
p-value2 0.68 0.16 0.16 0.50 0.68 0.81 0.84 0.84 1.00 0.81 
 
 
1 Odds ratio 
2 p-value is for a two-sided Fisher’s exact test, as implemented in R v3.1.1 (www.r-project.org). Comaprisons are considered significant at P < 0.05. 
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4.4 Discussion 
We examined genetic variability within and across the HLA class I loci in 111 treatment-naïve 
HIV-1 infected Black South Africans exhibiting differing degrees of viral control and in this 
way identified the residues within the HLA-A and HLA-B peptide binding grooves that strongly 
associate with HIV-1 control in this population group. Our findings confirm those from other 
populations, demonstrating the importance of HLA-B residues 67, 70, 97 and 116 in 
determining disease outcome (The International HIV Controllers Study et al., 2010; McLaren et 
al., 2012), while also identifying additional residues in HLA-A and -B that may potentially 
contribute to determining differential disease outcome in this population. We further 
demonstrate a lack of association between an indel polymorphism within the HLA-C 3’ UTR 
(rs67384697) and HIV-1 control in Black South Africans, a finding consistent with previous 
observations in African-Americans (McLaren et al., 2012).  
 
Recent evidence suggests that the effects of the most strongly protective HLA class I alleles may 
be lost in sub-Saharan African populations with high HIV-1 seroprevalence, as a consequence 
of viral adaptation to these alleles at the population level (Payne et al., 2014). Therefore, before 
analyzing the effects of individual SNPs within HLA class I loci on HIV-1 control, it was 
necessary to first establish whether the effects of these protective alleles were still of relevance 
in our cohort of HIV-1 progressors and controllers. Multivariate logistic regression analysis 
revealed B*57:03:01 and B*58:01:01 to be the alleles most strongly associated with HIV-1 
control in our cohort, consistent with previous reports in this population (Kiepiela et al., 2004; 
Leslie et al., 2010; Tang et al., 2011). Both these alleles, and particularly B*57:03:01, have 
been shown to limit viral replication through induction of strong CTL responses (Kiepiela et al., 
2004; Miura et al., 2009), as well as through their interaction with KIR3DL1 receptors NK cells 
(Martin et al., 2007; Kamya et al., 2011). 
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Positive associations with HIV-1 control were also observed for the B*39:10:01|C*12:03:01 
and B*81:01:01|C*04:01:01 haplotypes, both of which have previously been shown to be 
protective in the Black South African population (Kiepiela et al., 2004; Leslie et al., 2010). 
However, the mechanisms mediating the additive protective effects associated with these 
haplotypes have yet to be established. HLA-A*03:01:01, a known ligand for KIR3DL2 
(Döhring et al., 1996; Hansasuta et al., 2004), was the only allele seen to be significantly 
associated with a loss of viral control. Given that the interaction between A*03:01:01 and 
KIR3DL2 is peptide-specific (Hansasuta et al., 2004), presentation of viral peptides by 
A*03:01:01 may result in alterations in NK cell activity that cause a loss of viral control. This 
allele has previously been shown to be associated with reduced absolute CD4+ T cell count in 
Black South Africans (Leslie et al., 2010).  
 
Examination of individual SNPs within the HLA class I alleles observed within our cohort of 
HIV-1 progressors and controllers revealed 20 positions to be associated with differential HIV-1 
control. However, strong LD between SNPs within HLA loci resulted in only a limited number 
of independent associations. Residues in strong LD were also generally found to occur within 
the same structural features, making it difficult to establish whether the associations observed 
were attributable to a single residue or were, in fact, the result of the additive effects of all the 
residues comprising the haplotypes observed. 
 
Of the twelve positions identified within HLA-B, four (positions 67, 70, 97 and 116) had 
previously been observed to be associated with HIV-1 control in African-American (McLaren et 
al., 2012) and European-American (The International HIV Controllers Study et al., 2010) HIV-
1 progressors and -controllers. Of the eight additional residues observed to be associated with 
differential HIV-1 control in our cohort, alleles at position 70 were found to be in strong LD 
with those at positions 69 and 71, positions 24 and 41 were seen to be in strong LD with 
position 67, and alleles at position 32 were strongly associated with those at position 45.  
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Positions 24, 45, 67 and 70 all occur within the HLA-B α1 helix, the region of the molecule 
most critical to determining peptide specificity (Barber et al., 1997). Residue 67, in particular, is 
known to play an important role in determining the conformation of the B-pocket. The presence 
of bulky, hydrophobic, aromatic amino acids at this position limits the size of the B-pocket, 
sterically precluding binding of peptides containing amino acids with large side chains at 
position P2 (Smith et al., 1996). A similar effect has been observed at position 45 (Badrinath et 
al., 2012). Positions 97 and 116 within the β-strand of the α2 domain of HLA-B (Barber et al., 
1997; Sanjanwala et al., 2008; The International HIV Controllers Study et al., 2010; McLaren et 
al., 2012) and positions 149 and 152 within HLA-A α2 domain (Cowan et al., 1987; Hogan et 
al., 1988a; Hogan et al., 1988b) are also involved in modulating peptide specificity. These 
differences in peptide specificity are anticipated to result in differential regulation of CTL 
responses (Barber et al., 1997). 
 
While variability at position 116 has been shown to be important for regulating interactions with 
the C-terminal of the bound peptide (Barber et al., 1997; Macdonald et al., 2003; Zernich et al., 
2004), this residue has also been demonstrated to be vitally important in determining the nature 
of the interaction between HLA and tapasin (Rizvi et al., 2014). This interaction determines the 
dynamics of both HLA protein folding and peptide loading (Thammavongsa et al., 2006; Chen 
and Bouvier, 2007), such that more structurally stable tapasin-independent HLA allotypes may 
be loaded with low-affinity peptides and thus exhibit suboptimal antigen presentation to CD8+ T 
cells (Rizvi et al., 2014). Position 114 has also been implicated in determining tapasin 
dependence (Park et al., 2003). Both residues 114 and 116 in HLA-A were found to be 
associated with HIV-1 control. Tapasin-independent allotypes have previously been linked to 
rapid disease progression following HIV-1 infection (Rizvi et al., 2014). These positions were 
found to be in strong LD with each other, as well as positions 17 and 56. The resulting 
protective Ser17-Arg56-Glu114-His116 haplotype was found be unique to HLA-A30.  
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The differences in peptide specificity observed between HLA class I alleles are also known to  
differentially regulate the interactions of peptide-bound HLA to their cognate receptors on cell 
types other CD8+ T cells (Hansasuta et al., 2004; Sanjanwala et al., 2008; Jones et al., 2011). 
Variability at HLA-B residues 67, 97 and 116 has been shown to modulate the binding of HLA-
Bw4 molecules to KIR3DL1 (Sanjanwala et al., 2008). The interaction between KIR3DL1 and 
HLA-Bw4 is associated with increased NK responsiveness (Boulet et al., 2010; Kamya et al., 
2011; Parsons et al., 2012) and has been shown to be strongly associated with HIV-1 control 
(López-Vázquez et al., 2005; Martin et al., 2007; Kamya et al., 2011).  
 
Variability within the classical HLA class I molecules has also been found to differentially 
regulate their interaction with leukocyte immunoglobulin-like receptors (LILRs) (Jones et al., 
2011). Position 9 within all three classical HLA class I molecules has been shown to modulate 
their binding to LILRB2, in the absence of β2-microglobulin and peptide, as has position 144 
within HLA-A (Jones et al., 2011). High avidity binding of LILRB2 to HLA-B*35-Px 
molecules is thought to impede dendritic cell function and has been associated with more rapid 
HIV-1 disease progression (Huang et al., 2009). Conversely, HLA-B alleles with reduced 
LILRB2 binding affinities are associated with HIV-1 control (Bashirova et al., 2014). 
 
Although KIR (Moesta and Parham, 2012) and LILR (Jones et al., 2011) are both known to 
bind HLA-C in a peptide-specific manner, an association was not observed between HIV-1 
control and any of the residues examined within this molecule. This was consistent with results 
observed in African-Americans, where only variation occurring within the HLA-C α3 domain 
was shown to be associated with viral control (McLaren et al., 2012). The influence of genetic 
variability within HLA-C on HIV-1 control has also been attributed to an indel polymorphism at 
position 263 of the HLA 3’ UTR (rs67384697). Variability at this position has been shown to 
impact HLA-C expression by differentially regulating binding of specific miRNA to the HLA-C 
3’ UTR (Kulkarni et al., 2011; Kulkarni et al., 2013). Increased HLA-C expression has been 
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seen to be associated with HIV-1 control (Apps et al., 2013), and the deletion allele at this indel 
has been reported to be over-represented in HIV-1 controllers of European descent (Kulkarni et 
al., 2011).  
 
We, however, did not observe an association between possession of the 263D allele and HIV-1 
control, consistent with observations in African-American HIV-1 controllers (McLaren et al., 
2012). We did however note an increased frequency of the deletion allele at position 230 
(rs35877659) within the HLA-C 3’ UTR in HIV-1 controllers relative to progressors. We have 
previously hypothesized that due to strong LD between the two indels, variability at this 
position may also impact HLA-C expression through regulation of miRNA-binding, most 
dramatically when found in combination with the corresponding deletion allele at position 263 
(Chapter 3). Although this comparison did not reach statistical significance, we cannot exclude 
the possibility that variability at this position may influence HLA-C expression and thus HIV-1 
control. Our study may simply lack sufficient power to statistically validate this association, 
which may influence HIV-1 control in a manner more subtle than the associations observed in 
HLA-A and HLA-B.  
 
Collectively these data provide the first description of the impact of genetic variability at 
individual polymorphisms with the classical HLA class I loci on HIV-1 control in the Black 
South African population. These findings highlight the importance of HLA peptide specificity 
in determining immune responses to HIV-1 infection and suggest variability at key residues 
within the HLA molecule determine both the sequence of the peptide bound, as well as the 
avidity of the peptide-HLA interaction. The nature of these peptide-HLA interactions are likely 
to differentially impact the function of multiple immune cell types and thus have implications 
for future vaccine studies. Finally, we demonstrate that while the impact of HLA-C on HIV-1 
control is less subtle than that of HLA-A and HLA-B, the importance of this molecule in 
understanding antiviral immune responses should not be overlooked. 
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Chapter 5 
Genetic Variability within the KIR Gene Complex is 
Associated with HIV-1 Control and Distinguishes Elite 
Controllers from Viraemic Controllers 
 
5.1 Introduction 
The rate of HIV-1 disease progression is known to be highly variable between individuals. HIV-
1 controllers are a small subset of infected individuals capable of spontaneously suppressing 
viral replication and maintaining very low levels of viraemia (< 2000 RNA copies/ml) in the 
absence of highly active antiretroviral therapy. This ability to suppress viral replication has been 
shown to be associated with a number of both viral and host genetic characteristics, suggesting 
control of HIV-1 viral replication can be achieved through multiple immunological mechanisms 
(Deeks and Walker, 2007; Walker and Yu, 2013).  
 
The argument for the existence of multiple mechanisms of HIV-1 control is further supported 
by the observation that a small percentage of HIV-1 controllers, known as elite controllers, can 
be further distinguished from other controllers by their ability to suppress viral replication to 
levels undetectable by currently available commercial assays (<50 RNA copies/ml; Deeks and 
Walker, 2007). Whether elite controllers employ entirely different immune mechanisms of viral 
control, or simply more effectively utilize the same mechanisms as other HIV-1 controllers, 
remains unclear. Therefore, identification and characterization of the immune signatures that 
distinguish elite controllers from other HIV-1 controllers is necessary. 
 
Genetic variability within the HLA gene complex has been identified as one of the major 
determinants of HIV-1 control (Fellay et al., 2007; The International HIV Controllers Study, 
2010). HLA class I alleles function as ligands for both the TCR found on the surface of CD8+ T 
cells, and specific KIR expressed predominantly on the surface of NK cells. While the impact of 
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HLA-restricted CTL responses on HIV-1 control has been well established (Migueles et al., 
2003; Kiepiela et al., 2007; Sáez-Cirión et al., 2007), the role of NK cell-mediated immunity in 
modulating viral control during chronic HIV-1 infection is only just beginning to be understood 
(Alter et al., 2011). 
 
KIR receptors are encoded by a family of highly polymorphic genes located on chromosome 19 
(Wilson et al., 2000; Martin et al., 2000). Diversity in terms of KIR gene content is determined 
by two KIR haplotypes (Uhrberg et al., 2002; Martin et al., 2004), which are themselves the 
product of varying combinations of centromeric and telomeric gene content motifs (Pyo et al., 
2010; Jiang et al., 2012; Vierra-Green et al., 2012; Pyo et al., 2013). Genetic variability within 
KIR loci has previously been shown to be associated with both HIV-1 transmission (Jennes et 
al., 2006; Merino et al., 2011; Paximadis et al., 2011; Hong et al., 2013) and disease 
progression (Martin et al., 2002a; Martin et al., 2007; Jennes et al., 2011). We therefore 
examined patterns of genetic variability within the KIR and HLA gene complexes in 111 
treatment-naïve HIV-1 infected Black South Africans exhibiting differing degrees of viral 
control. These data reveal an association between common KIR haplotypes and HIV-1 control in 
a population heavily affected by the HIV/AIDS pandemic. 
 
5.2 Materials and Methods 
5.2.1 Study Populations 
A total of 111 treatment-naïve HIV-1 infected Black South Africans were included in this study 
in order to investigate the impact of genetic variability within the KIR gene complex on control 
of HIV-1 infection. Sixty-nine of these individuals were classified as HIV-1 progressors based 
on a CD4+ T cell count that declined to below 300 cells/mm3 prior to the administration of ART. 
As decisions to commence ART are based solely on CD4+ T cell count, which may then include 
HIV-1 controllers (viraemic or elite) with declining counts, we included the criterion of high 
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viraemia (i.e. viral loads greater than 10 000 RNA copies/ml) to identify progressors (Table 
4.1).  
 
The remaining 42 HIV-1 positive individuals were classified as HIV-1 controllers on the basis 
of their having CD4+ T counts greater than 300 cells/mm3, while also suppressing viral 
replication to levels below 2000 RNA copies/ml. Eleven of these HIV-1 controllers could be 
categorized as elite controllers as a consequence of their ability to maintain viral loads below 50 
RNA copies/ml - based on counts taken on two or more occasions, recorded at least 12 months 
apart. The remaining 31 HIV-1 controllers exhibited viral loads between 50 and 2000 RNA 
copies/ml and were, for the purposes of this study, regarded as viraemic controllers.  
 
HIV-1 RNA levels were quantitated using either the Roche Amplicor RNA Monitor assay 
(lower detection limit of 400 HIV-1 RNA copies/ml) or, where necessary, the COBAS 
AmpliPrep/COBAS Taqman HIV-1 Test, v2.0 (Roche Molecular Diagnostics, Pleasanton, 
California, USA), which has a lower detection limit of 50 RNA copies/ml. CD4+ T cell counts 
were determined using the FACSCount System (BD Biosciences, San Jose, California, USA). 
Informed consent was obtained from all study participants and the study was approved by the 
University of the Witwatersrand Committee for Research on Human Subjects (Appendix B). 
 
5.2.2 DNA Extraction 
The DNA obtained from HIV-1 controllers was extracted from whole blood samples, while that 
obtained from HIV-1 progressors was derived from frozen buffy coat samples. DNA extractions 
from all HIV-1 infected samples were performed by silica spin-column purification using the 
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).  
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5.2.3 KIR Genotyping 
Individuals were genotyped for the presence or absence of 16 KIR genes using a real-time PCR 
assay (Hong et al., 2011), as previously described (Chapter 2, Section 2.2.2). Additional primers 
(Jiang et al., 2012) were included to distinguish between KIR2DS4 alleles encoding the full 
length form of the receptor (KIR2DS4f) and alleles encoding a deleted form of the gene 
(KIR2DS4v). All individuals were assigned either AA or Bx KIR genotypes, according to the 
guidelines and nomenclature stipulated by the Allele Frequency Net Database (Gonzalez-
Galarza et al., 2011); and individual KIR haplotypes were inferred using HAPLO-IHP (Yoo et 
al., 2007), as previously described (Chapter 2, Section 2.2.4). 
 
5.2.4 KIR Copy Number Determination 
KIR3DL1 and KIR3DS1 copy number was determined using a quantitative real-time PCR assay, 
as described by Pelak et al. (2011). Standard curves were derived from serial dilution of 
genomic DNA obtained from the CEPH cell lines GM11840 and GM12752 (which are known 
to possess single copies of KIR3DL1 and KIR3DS1), with concentrations ranging between 20 
and 0.625 ng/µl. Primers specific for the dual copy housekeeping gene, beta-globin (BGB; 
Shostakovich-Koretskaya et al., 2009), were included as an internal control. KIR2DS4f and 
KIR2DS4v copy number was similarly determined using the primers and probes of Jiang et al. 
(2012). 
 
For both assays, reactions were performed in a 5 µl volume, containing 2x Lightcycler 480 
Probes Master (Roche, Mannheim, Germany), 0.5 µM of each primer, 0.1µM of VIC®-labelled 
gene-specific probe, 0.1µM of 6-carboxyfluorescein (FAM)-labelled BGB-specific probe (Life 
Technologies, Carlsbad, California, USA) and 5 ng of DNA. Both assays was performed using 
the Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems, Foster City, 
California, USA), under the following thermocycling conditions: 95°C for 10 minutes, followed 
  
79
by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Reactions were performed in 
duplicate for all samples, or triplicate, if the initial results were discordant. 
 
5.2.5 HLA Class I Ligand Determination 
HLA-A, -B and -C genotype data were available for all 111 individuals included in this study 
(Paximadis et al., 2012; Chapter 3, Section 3.2.2; Chapter 4, Section 4.2.3). HLA-A and -B 
Bw4 isotopes within alleles were identified based on the amino acid residues present at 
positions 77, 80, 81, 82 and 83 of the protein sequence (Martin et al., 2002a). A further 
distinction was made between HLA-B alleles with isoleucine at amino acid position 80 (Bw4-
80I) and those with threonine at this position (Bw4-80T), as these epitopes differ in the avidity 
of their interaction with KIR3DL1 (Cella et al., 1994; Martin et al., 2002a). HLA-C alleles were 
similarly classified as having either HLA-C1 or –C2 epitopes on the basis of the presence of 
asparagine or lysine at position 80, respectively (Colonna et al., 1993; Winter and Long, 1997). 
 
5.2.6 Statistical Analyses 
KIR gene carrier- and HLA class I ligand frequencies were determined by direct counting. The 
significance of differences in the frequencies observed between groups was assessed using a 
two-sided Fisher’s exact test and the associated odds ratios were estimated. Odds ratios greater 
than 1 indicate a positive association with HIV-1 control. Differences in gene copy number 
between groups were assessed using a non-parametric Mann-Whitney U-test. All statistical 
analyses were conducted using R v3.1.1 (www.r-project.org) and all measures were considered 
significant at p < 0.05.  
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5.3 Results 
5.3.1 KIR Gene Diversity 
In order to investigate the association between genetic variability within the KIR gene complex 
and HIV-1 control, we examined gene diversity at this locus in HIV-1 progressors, viraemic 
controllers and elite controllers (Figure 5.1). HIV-1 progressors were found to differ from 
viraemic controllers in that individuals within this group were less likely to be in possession of 
KIR2DL5 (p = 0.036; OR = 3.3; CI = 1.1 – 9.8) and KIR2DS5 (p = 0.031; OR = 2.7; CI = 1.1 – 
6.7), but displayed KIR2DL3 frequencies greater than that seen in the viraemic controller group 
(p = 0.046; OR = 0.4; CI = 0.1 – 0.9). Viraemic controllers, in turn, were distinguished from 
elite controllers, by displaying a greater frequency of KIR2DS5 (p = 0.033; OR = 0.2; CI = 0.0 – 
0.8) and a decreased likelihood of being in possession of KIR2DL3 (p = 0.018; OR = ∞). HIV-1 
progressors were also found to possess significantly fewer copies of both KIR2DS4 (p = 0.035) 
and KIR3DL1 (p = 0.029) per individual than HIV-1 controllers (i.e. individuals with viral loads 
below 2000 RNA copies/ml). 
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Figure 5.1: The gene carrier frequencies of the KIR genes present within HIV-1 progressors, viraemic controllers and elite controllers. The four framework KIR 
genes (KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1) were present in all individuals and are thus not shown. KIR2DL1, KIR2DP1 and KIR3DL1 
were also present in more than 98% of individuals in all groups considered and their frequencies are thus also not shown. The frequencies of 
KIR2DS4 are reported for its two isoforms, the cell surface receptor, KIR2DS4f and the secreted receptor, KIR2DS4v. Significant comparisons        
(p < 0.05), as measured by a two-sided Fisher’s exact test, are indicted with an asterisk. 
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5.3.2 KIR Genotype Distributions 
The differences in gene frequencies seen between HIV-1 progressors and -controllers (i.e. all 
individuals with viral loads below 2000 RNA copies/ml) translated into noticeable differences 
in their KIR genotype profiles (Table 5.2), with the Bx 5 and Bx 112 genotypes being observed 
more frequently in HIV-1 controllers than progressors. While these comparisons did not reach 
statistical significance, it is worth noting that the frequencies of the Bx 5 (p = 0.032) and         
Bx 112 (p = 0.010) genotypes observed in HIV-1 controllers were significantly higher than 
those generally observed in the Black South African population (Chapter 2, Table 2.2). 
Furthermore, the Bx 5 genotype was found to be especially over-represented within elite 
controllers, while the Bx 112 was found to be absent from this group all together (Figure 5.2). 
These two observations were indicative of a pattern that emerged between the two groups, 
whereby genotypes containing KIR2DS5 were more commonly observed in HIV-1 viraemic 
controllers than in elite controllers, who most often possessed KIR genotypes containing 
KIR2DS3. 
 
5.3.3 Estimation of KIR Haplotypes 
Further analysis of the KIR genotypes present in Black South African HIV-1 progressors and 
controllers revealed they were comprised of a total of 23 KIR haplotypes (Table 5.3), which 
were themselves the result of varying combinations of three centromeric and two telomeric 
haplotype motifs (Pyo et al., 2010; Pyo et al., 2013). The canonical cA01|tA01 haplotype was 
found to be the most frequently observed haplotype within both HIV-1 progressors and elite 
controllers, while viraemic controllers were distinguished from progressors (p = 3.46 x 10-4; OR 
= 3.7; CI = 1.9 – 7.5) and elite controllers (p = 0.035; OR = 0.3; CI = 0.1 – 0.9) by an unusually 
high frequency of the archetypal cB01|tA01 haplotype (Table 5.3).  
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Table 5.1 The frequencies of the KIR genotype profiles present within HIV-1 progressors and -controllers  
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 HIV-1 HIV-1 HIV-1 
KIR Progressors Viremic Elite 
Genotype 
  
Controllers Controllers 
  
(n = 69) (n = 31) (n = 11) 
AA 1                                 0.290 (20) 0.161 (5) 0.182 (2) 
Bx 21                                 0.130 (9) 0.194 (6) - 
Bx 5                                 0.116 (8) 0.129 (4) 0.455 (5) 
Bx 4                                 0.087 (6) - 0.091 (1) 
Bx 20                                 0.072 (5) 0.097 (3) 0.091 (1) 
Bx 9                                 0.058 (4) - - 
Bx 71                                 0.058 (4) - - 
Bx 112                                 0.058 (4) 0.194 (6) - 
Bx 6                                 0.029 (2) - 0.091 (1) 
Bx 92                                 0.029 (2) - - 
Bx 2                                 0.014 (1) - - 
Bx 3                                 0.014 (1)   0.091 (1) 
Bx 73                                 0.014 (1) 0.065 (2) - 
Bx 172                                 0.014 (1) - - 
Bx 228                                 0.014 (1) 0.097 (3) - 
Bx 38                                 - 0.032 (1) - 
Unknown                                 - 0.032 (1) - 
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Figure 5.2: The KIR genotypes present in HIV-1 viraemic- and elite controllers and their frequencies. The presence of KIR2DS3 and KIR2DS5 within genotypes 
is highlighted. Significantly differences in frequency (p < 0.05) between the two groups, as measured by a two-sided Fisher’s exact test, are indicated 
with an asterisk. 
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Table 5.2 The frequencies of the KIR haplotypes occurring within HIV-1 progressors,       
-viraemic controllers and -elite controllers  
 
 
HIV-1 
Progressors 
(n = 69) 
HIV-1 Viraemic 
Controllers 
(n = 31) 
HIV-1 Elite 
Controllers 
(n = 11) 
 n Frequency n Frequency n Frequency 
cA01|tA011 52 0.377 20 0.323 10 0.455 
cA01|tA01-hybd12 13 0.094 2 0.032 2 0.091 
cA01|tA01-del5 11 0.080 1 0.016 1 0.045 
cA01/cB03|tB013 1 0.007 0 0.000 0 0.000 
cB01|tA01 20 0.145 24 0.387 3 0.136 
cB01|tA01-hybd1 2 0.014 2 0.032 1 0.045 
cB01|tA01-del3 4 0.029 5 0.081 1 0.045 
cB01|tA01-del5 11 0.080 2 0.032 1 0.045 
cB01|tA01-del9 8 0.058 0 0.000 1 0.045 
cB01|tA01-del3-del5 1 0.007 0 0.000 0 0.000 
cB01|tA01-del3-del5-del9 0 0.000 1 0.016 0 0.000 
cB01|tB01 4 0.029 2 0.032 1 0.045 
cB01|tB01-del7 6 0.043 1 0.016 0 0.000 
cB02|tA01-hybd1 5 0.036 1 0.016 0 0.000 
cB02|tB01 0 0.000 0 0.000 1 0.045 
H24 0 0.000 1 0.016 0 0.000 
 
 
                 1  Major haplotypes comprised of the classic centromeric and telomeric KIR motifs are indicated in grey. 
                 2 Minor haplotypes including gene insertions, deletions, duplications and hybrid genes are named in  
              accordance with the nomenclature of Pyo et al. (2013). 
                 3 cA01|tB01 and cB03|tB01 could not be distinguished from each other and are reported as cA01/cB03|tB01. 
                 4 Haplotypes that could not be named according to the aforementioned nomenclature were assigned arbitrary  
             designations based on their frequencies within the Black South African population (Table 2.2). 
 
5.3.4 Examination of KIR Haplotype Motifs 
The high frequencies of the cA01|tA01 and cB01|tA01 haplotypes observed in all three 
groups were found to be a reflection of the high frequencies of the cA01 and cB01 centromeric 
haplotype motifs (Pyo et al., 2010; Pyo et al., 2013) within these groups. Collectively, these two 
motifs accounted for the centromeric component of more than 95% of the haplotypes occurring 
in all three groups. However, while the cA01 motif was the centromeric motif most frequently 
observed in HIV-1 progressors and -elite controllers, the cB01 motif was the centromeric motif 
seen at the highest frequency in viraemic controllers (Figure 5.3).  
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Figure 5.3: The frequencies of the centromeric KIR haplotype motifs observed within HIV-1 
progressors, viraemic controllers and elite controllers. The cA01/cB01|tB01 haplotype 
from one HIV-1 progressor has been omitted from the analyses. The odds ratios and p-
values associated with significant differences in frequency between groups (p < 0.05), 
as measured by a two-sided Fisher’s exact test, are indicated. 
 
 
The canonical cB01 centromeric KIR haplotype motif may contain either KIR2DS3 or KIR2DS5 
(Pyo et al., 2010). A truncated motif lacking either of these genes has also been identified 
(cB01-del9; Pyo et al., 2013). Given the variability in KIR2DS3 and KIR2DS5 frequencies 
displayed across the groups included in this study, we examined the distribution of cB01 gene 
content variants within the three groups. Elite controllers were distinguished from both 
progressors (p = 0.048; OR = 5.8; CI = 1.1 – 31.8) and viraemic controllers (p = 0.055; OR = 
5.5; CI = 1.0 – 31.5) by their higher frequency of cB01 motifs containing KIR2DS3 rather than 
KIR2DS5. Conversely, cB01 motifs containing KIR2DS5 were more commonly observed within 
viraemic controllers than elite controllers (p = 0.007; OR = 0.1; CI = 0.0 – 0.7).  
 
 
Elite controllers could also be distinguished from the other two groups by their high degree of 
heterozygosity with respect to centromeric KIR haplotype motifs, as more than 80% of elite 
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controllers were found to possess both cA and cB haplotype motifs (Figure 5.4). Viraemic 
controllers, on the other hand, were most likely to possess two copies of a cB haplotype motif, a 
characteristic not seen in any of the elite controllers. 
 
 
Figure 5.4: The frequencies of the centromeric KIR haplotype motif combinations observed in 
HIV-1 progressors, viraemic controllers and elite controllers. The odds ratios associated 
with significant differences in frequency between groups (p < 0.05), as measured by a 
two-sided Fisher’s exact test, are indicated. 
 
 
In contrast with centromeric B motifs, the telomeric tB01 motif was present at similarly low 
frequencies in HIV-1 progressors and -controllers (data not shown); with the result that the tA01 
motif was present in more than 90% of haplotypes in all three groups. Telomeric tA01 motifs 
lacking KIR3DL1 (tA01-del5) were found to occur at a significantly higher frequency in 
progressors than HIV-1 controllers (p = 0.046; OR = 0.4; CI = 0.1 – 1.0). tA01 motifs lacking 
any form of KIR2DS4 (tA01-hybd1) were also found to occur at a greater frequency in 
progressors than controllers, but this comparison did not reach statistical significance. 
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5.3.5 Association between Specific KIR and their HLA Class I Ligands 
5.3.5.1 HLA-B and KIR3DL1 
KIR receptors are involved in the regulation of NK cell function, predominantly through their 
interaction with HLA class I molecules (Lanier, 1998). One of these receptors is KIR3DL1, 
which is known to bind the HLA-Bw4 epitopes present within a subset of both HLA-A 
(Thananchai et al., 2007, Stern et al., 2008) and HLA-B (Cella et al., 1994; Gumperz et al., 
1995, Vivian et al., 2011) molecules. Interactions between KIR3DL1 (Martin et al., 2007) - and 
the activating form of this receptor, KIR3DS1 (Martin et al., 2002a) - and Bw4 have previously 
been shown to be associated with control of HIV-1 infection. However, KIR3DS1 was found to 
occur at very low frequencies in all the groups included in the current study (Figure 5.1) - an 
observation consistent with previous studies conducted in other African populations (Norman et 
al., 2007; Single et al., 2007). Given our sample size, this made it difficult to realistically assess 
the impact of KIR3DS1 co-occurrence with Bw4 on HIV-1 control in the Black South African 
population. 
 
We therefore turned our attention to the co-occurrence of KIR3DL1 and the HLA-A and –B 
alleles encoding its Bw4 ligand in HIV-1 progressors and controllers. KIR3DL1 was generally 
found to occur in combination with Bw4 at lower frequencies in HIV-1 controllers than in 
progressors. However, when a distinction was made between alleles encoding Bw4 epitopes 
with isoleucine at position 80 (Bw4-80I) and those with threonine at position 80 (Bw4-80T), it 
became clear that Bw4-80T occurs in combination with KIR3DL1 at higher frequencies in 
progressors and viraemic controllers than in elite controllers (Table 5.3). Bw4-80I, on the other 
hand was found to occur in combination with KIR3DL1 at higher frequencies in progressors 
than in HIV-1 controllers. This was particularly true of the Bw4-80I epitopes present in HLA-A 
alleles, which were not found to occur in elite controllers (Table 5.3). However, despite these 
  
89
seemingly clear distinctions, none of these comparisons were found to reach statistical 
significance. 
 
Table 5.3 The frequency with which KIR3DL1 occurs in combination with HLA-A and 
HLA-B alleles encoding its Bw4 ligand in HIV-1 progressors, viraemic 
controllers and elite controllers 
 
 
 
HIV-1  
Progressors 
(n = 69) 
HIV-1 Viraemic 
Controllers 
(n = 31)1 
HIV-1 Elite 
Controllers 
(n = 11) 
 n Frequency n Frequency n Frequency 
KIR3DL1 + Bw4 50 0.725 19 0.679 7 0.636 
KIR3DL1 + HLA-A Bw4 20 0.290 4 0.174 0 0.000 
KIR3DL1 + HLA-B Bw4 41 0.594 17 0.548 7 0.636 
KIR3DL1 + Bw4-80I 43 0.623 15 0.536 5 0.455 
KIR3DL1 + HLA-A Bw4-80I 20 0.290 4 0.174 0 0.000 
KIR3DL1 + HLA-B Bw4-80I 27 0.391 15 0.536 5 0.455 
KIR3DL1 + Bw4-80T 19 0.275 7 0.226 2 0.182 
 
 
     1 Only 23 viraemic controllers were genotyped at the HLA-A locus. 
 
5.3.5.2 HLA-C and its Associated KIR Receptors 
The HLA-C1 and -C2 epitopes present in virtually all HLA-C alleles also serve as ligands for 
the KIR receptors, KIR2DL2, KIR2DL3, KIR2DL1 and KIR2DS1 (Colonna et al., 1993; 
Winter and Long, 1997; Winter et al., 1998, Moesta et al., 2010). We therefore examined the 
co-occurrence of these KIR genes and the HLA-C alleles encoding the C1 and C2 epitopes in 
HIV-1 progressors and controllers (Table 5.4). The progressor group was found to differ from 
viraemic controllers in having a higher frequency of KIR2DL3 in combination with HLA-C1, 
while viraemic controllers in turn, differed from elite controllers by having a lower frequency of 
KIR2DL3 in combination with HLA-C2; although neither of these comparisons were found to 
reach statistical significance. 
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Table 5.4 The frequencies with which KIR2DL1, KIR2DL2, KIR2DL3 and KIR2DS1 
occur in combination with HLA-C alleles encoding the C1 and C2 epitopes in 
HIV-1 progressors, -viraemic controllers and -elite controllers 
 
 
 
HIV-1 
Progressors 
(n = 69) 
HIV-1 Viraemic 
Controllers 
(n = 31) 
HIV-1 Elite 
Controllers 
(n = 11) 
n Frequency n Frequency n Frequency 
HLA-C1       
KIR2DL1 + C1 49 0.710 21 0.677 6 0.545 
KIR2DL2 + C1 33 0.478 17 0.548 4 0.364 
KIR2DL3 + C1 40 0.580 12 0.387 6 0.545 
KIR2DS1 + C1 8 0.116 2 0.065 1 0.091 
HLA-C2       
KIR2DL1 + C2 56 0.812 23 0.742 9 0.818 
KIR2DL2 + C2 38 0.551 20 0.645 9 0.818 
KIR2DL3 + C2 45 0.652 15 0.484 9 0.818 
KIR2DS1 + C2 10 0.145 3 0.097 2 0.182 
 
 
5.4 Discussion 
Epidemiological studies have previously shown the presence of specific KIR receptors to be 
associated with HIV-1 control; both in conjunction with and independently of their HLA 
encoded ligands (Martin et al., 2002a; Martin et al., 2007; Jennes et al., 2011; Pelak et al., 
2011). Further functional studies (Alter et al., 2007; Merino et al., 2014) have since supported 
these findings by demonstrating the impact of these receptors on NK cell function, in the 
context of the immune dysregulation brought about as a consequence of HIV-1 infection (Wong 
et al., 2010). In light of these observations, we sought to examine the association between the 
presence of specific KIR receptors, and their HLA class I ligands, and control of HIV-1 
infection in the Black South African population - one of the populations most heavily impacted 
by the HIV/AIDS pandemic. 
 
In order to do this, we examined genetic variability within the KIR and HLA gene complexes in 
111 HIV-1 infected, treatment-naïve, Black South Africans with differing levels of viral control. 
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This cohort was comprised of 69 HIV-1 progressors and 42 HIV-1 controllers, 11 of whom 
were elite controllers, able to suppress viral replication to levels undetectable by commercially 
available assays. Our analysis revealed these groups could be clearly distinguished from each 
other based on a number of differences in KIR gene content and copy number. HIV-1 
progressors were most notably distinguished from HIV-1 controllers by having significantly 
fewer copies of KIR2DS4 and KIR3DL1. These differences could be attributed to the increased 
frequency of truncated telomeric tA01 KIR haplotype motifs lacking either KIR2DS4 (tA01-
hybd1) or KIR3DL1 (tA01-del5) in this group.  
 
While an association between KIR2DS4 copy number and HIV-1 control has not previously 
been reported, this gene has been shown to be associated with mother-to-child transmission of 
HIV-1 in the Black South African population (Hong et al., 2013). KIR2DS4, and in particular 
allelic variants encoding receptors capable of cell surface expression, have also been shown to 
be associated with increased viral loads and likelihood of HIV-1 transmission in heterosexual 
Zambian couples (Merino et al., 2011). While the precise mechanism responsible for this 
observed association has yet to be ascertained, it has been suggested that this receptor may 
promote HIV-1 pathogenesis by contributing to the maintenance of a pro-inflammatory state 
during chronic infection (Merino et al., 2014). Our data, however, conflict with these previous 
observations in that we find a significant underrepresentation of KIR2DS4 in HIV-1 progressors 
that suggests the lack of KIR2DS4 to be associated with unfavorable HIV-1 disease outcomes. 
These conflicting findings would suggest that further investigation of the role of KIR2DS4 in 
both HIV-1 transmission and disease progression is warranted. 
 
In contrast with KIR2DS4, the  association between copy number variation across the KIR3DL1 
locus and HIV-1 control has previously been examined in individuals of European descent - 
where an inverse correlation between HIV-1 set point and increased KIR3DL1 copy number was 
observed in individuals who were also in possession of KIR3DS1 and a corresponding HLA-
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Bw4 ligand (Pelak et al., 2011). We similarly report a positive correlation between lower 
KIR3DL1 copy number and an inability to suppress HIV-1 viral replication. However, we found 
this association to be independent of the presence of either KIR3DS1 or the HLA Bw4 epitope. 
 
Unlike previous reports (Martin et al., 2002a; Long et al., 2008; Jiang et al., 2013), we did not 
observe an association between the presence of KIR3DS1 and HIV-1 control; and due to the low 
frequency of this gene in the Black South African population, our study lacked the power to 
adequately assess the impact of KIR3DS1 co-occurrence with Bw4 on HIV-1 control. While we 
cannot rule out a potential role for KIR3DS1 in determining HIV-1 disease outcome, 
particularly in light of the findings of studies conducted in other populations (Martin et al., 
2002a; Long et al., 2008; Jiang et al., 2013), it could be suggested that, at least at the greater 
population level, the impact of this receptor on HIV-1 control in the Black South African 
population may not be as profound as that seen in other non-African populations. 
 
HIV-1 controllers could also be distinguished on the basis of their KIR gene content, as they 
were found to possess KIR2DL2, KIR2DL5 and KIR2DS3 more frequently than HIV-1 
progressors. Viraemic- and elite controllers could be further distinguished by their differing 
frequencies of KIR2DL3 and KIR2DS5. These differences in gene content could be attributed to 
the increased frequency of the cB01|tA01 KIR haplotype seen in HIV-1 controllers. But while, 
viraemic controllers in possession of these haplotypes most frequently carried haplotypes with 
cB01 motifs containing KIR2DS5, elite controllers were most often found to carry cB01 motifs 
containing KIR2DS3.  
 
The differing gene content of the cB01 haplotype motifs observed in viraemic- and elite 
controllers could also account for the differences in KIR genotype frequencies observed between 
these two groups; where viraemic controllers displayed a high frequency of Bx 112, elite 
controllers predominantly possessed the Bx 5 genotype. The presence/absence KIR gene profile 
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associated wit the Bx 5 genotype can most easily be achieved as a result of having a KIR2DS3-
containing cB01|tA01 haplotype in combination with cA01|tA01 haplotype, while the Bx 112 
genotype is easily derived from the combination of KIR2DS3- and KIR2DS5-containing 
cB01|tA01 haplotypes. 
 
While these observations point to a clear association between possession of cB01 (particularly 
KIR2DS3-containing) haplotype motifs and HIV-1 control, the functional rationale for this 
correlation is less apparent. Despite KIR2DS3 and KIR2DS5 both being lineage III KIR, and 
thus structurally most closely resembling those KIR that recognize HLA-C (Moesta and 
Parham, 2012), as seen with KIR2DS2, there is no functional evidence to support recognition of 
HLA-C by either of these receptors (Chiesa et al., 2008). Both receptors are also known to 
display markedly reduced levels of surface expression relative to the HLA-C-recognizing 
receptor, KIR2DS1 (Steiner et al., 2008; VandenBussche et al., 2008; Steiner et al., 2014). 
However, more highly expressed KIR2DS5 variants have been shown to be capable of 
triggering both NK cytotoxicity and cytokine production (Chiesa et al., 2008; Steiner et al., 
2014), which could indicate that like KIR2DS4 (Katz et al., 2004), KIR2DS5 may engage with 
as yet unidentified non-HLA ligands in order to activate NK function. 
 
Alternatively, the presence of KIR2DS3 or KIR2DS5 may act as markers for specific allelic 
variants of the inhibitory receptors KIR2DL1 and/or KIR2DL2, both of which are known to 
regulate NK cell function through interaction with HLA-C (Colonna et al., 1993; Winter and 
Long, 1997). KIR2DS3 and KIR2DS5, like KIR2DL2 and KIR2DL3, effectively represent alleles 
of the same locus and strong linkage disequilibrium between KIR2DL5, KIR2DS3/2DS5 and 
KIR2DL2/2DL3 has previously been reported in this (Chapter 2, Section 2.3.4) and other 
African populations (Hou et al., 2010; Nakimuli et al., 2013; Norman et al., 2013). Supporting 
this explanation are the observations that a KIR2DS3-containing haplotype has previously been 
associated with increased risk of chronic HCV infection (Dring et al., 2011), while KIR2DS5-
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containing haplotypes are associated with a reduced risk of developing pre-eclampsia in African 
women (Nakimuli et al., 2015).  
 
Allelic variability is known to modify the structure of both KIR2DL1 and KIR2DL2 in a 
manner that could potentially impact on their function (VandenBussche et al., 2006; Bari et al., 
2009; Hilton et al., 2012; Frazier et al., 2013). These variations may affect the levels of receptor 
expression at the cell surface (VandenBussche et al., 2006) or modify the avidity of receptor-
ligand interactions (Hilton et al., 2012; Frazier et al., 2013). The same is true of KIR3DL1 
(Pando et al., 2003; Carr et al., 2005), for which allelic variability has already been shown to be 
associated with HIV-1 control in individuals in possession of a corresponding HLA-Bw4 ligand 
(Lopez Vasquez et al., 2005; Martin et al., 2007). The involvement of KIR allelic polymorphism 
in HIV-1 control could thus account for why we did not see a significant difference in the 
frequencies of KIR-HLA ligand pairs between HIV-1 controllers and progressors. If differences 
in the immune mechanisms employed by individuals in either group are indeed mediated by 
allelic micro-alterations in KIR receptor structure, it would be beyond the power of the present 
study to detect these associations.  
 
Regardless, our data provide the first description of genetic variability within the KIR gene 
complex in Black South African HIV-1 controllers and progressors. We demonstrate a clear 
association between telomeric KIR tA01 haplotype motifs lacking either KIR2DS4 and 
KIR3DL1 and the loss of control of HIV-1 replication, while concurrently demonstrating an 
association between the presence of specific cB01 centromeric haplotype motifs and the ability 
to spontaneously suppress viral replication. We further observed the presence of KIR2DS3 
(rather than KIR2DS5) within these cB01 motifs and concomitant heterozygosity with cA01 
motifs to be significantly associated with HIV-1 elite controller status. Collectively, these data 
point to a potentially important role for NK cell-mediated immunity in HIV-1 control in the 
Black South African population. 
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Chapter 6 
Concluding Remarks 
 
The rate of HIV-1 disease progression is known to vary, often dramatically, between 
individuals. A small subset of infected individuals, termed HIV-1 controllers, are able to 
maintain very low levels of viraemia (< 2000 RNA copies/ml) in the absence of highly active 
antiretroviral therapy. A still smaller percentage of individuals, known as elite controllers, can 
be further distinguished from other controllers by their ability to suppress viral replication to 
levels undetectable by currently available commercial assays (Deeks and Walker, 2007). It is 
thought that an understanding of the genetic and immunological characteristics that define these 
individuals may provide insights pertinent to the development of an HIV-1 vaccine and/or other 
potential therapeutic interventions (Walker and Yu, 2013).   
 
However, attempts to characterize the host genetic, viral and immunological signatures 
associated with natural control of HIV infection have revealed HIV-1 controllers to be a 
heterogeneous group and have suggested that multiple immune mechanisms may be employed 
in order to control HIV-1 replication (Walker and Yu, 2013). Genetic variability within the HLA 
class I loci is widely recognized as one of the major determinants of HIV-1 control (Goulder 
and Walker, 2012). GWAS studies have revealed polymorphic variants within the HLA gene 
complex to be the genetic factors most strongly associated with viral control (Fellay et al., 2007; 
The International HIV Controller Study, 2010) and a number of HLA alleles have been 
associated with differential HIV-1 disease outcome (Kiepiela et al., 2004; Lazaryan et al., 2006; 
Leslie et al., 2010; Tang et al., 2011). More recently, individual polymorphisms within both the 
coding (The International HIV Controller Study, 2010; McLaren et al., 2012) and regulatory 
regions surrounding these genes (Kulkarni et al., 2011; Ballana et al., 2012) have also been 
shown to be associated with viral control.  
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HLA class I molecules are crucial regulators of the host response to viral infection, mediating 
both adaptive and innate immune responses through their interactions with both the TCR and 
KIR on the surface of NK cells. As a result, the loci encoding these receptors have evolved to be 
the most polymorphic in the human genome (Robinson et al., 2014). This high level of 
variability often lead to differences in the allele distributions and patterns of linkage 
disequilibrium across these loci being observed between populations with distinct demographic 
histories (Cao et al., 2001; Cao et al., 2004; Paximadis et al., 2012). These differences, if 
unaccounted for, have the potential to confound disease association studies. Therefore, a 
thorough prior understanding of the patterns of genetic variability present within ones 
population of interest is necessary in order to fully understand the nature of potential 
correlations observed during disease association studies.  
 
While allelic patterns of genetic variability across the HLA class I loci within the Black and 
Caucasian South African population groups had previously been reported (Paximadis et al., 
2012) prior to the commencement of this study, a description of the patterns of variation within 
the non-coding regulatory regions upstream (-35 SNP; rs9264942) and downstream (263 indel; 
rs67384697) of HLA-C in the South African population had not yet been reported. The -35 SNP 
was initially identified as one of the genetic variants most strongly associated with lower HIV-1 
viral set point (Fellay et al., 2007). The -35C allele at this position had also previously been 
shown to be strongly associated with increased HLA-C mRNA expression in Epstein-Barr 
virus-transformed B-cell lines (Stranger et al., 2005). Therefore, the association observed 
between the -35C allele and HIV-1 control was thought to stem from differential regulation of 
HLA-C expression at this position (Fellay et al., 2007). 
 
However, the association seen between this SNP and HIV-1 viral set point in individuals of 
European descent (Fellay et al., 2007), was not observed in African-Americans (Shrestha et al., 
2009); suggesting that variability at this SNP was not responsible for the observed alterations in 
  
97
HLA-C expression, but rather acted as marker for the true causal variant (Corrah et al., 2009). 
The 263 indel was subsequently identified as the variant responsible for mediating differential 
HLA-C expression (Kulkarni et al., 2011; Kulkarni et al., 2013) and was shown to be in strong 
LD with the -35 SNP in European-Americans (Kulkarni et al., 2011). We therefore examined 
and characterized variability at these two positions in individuals from the Black and Caucasian 
South African population groups, in order to both confirm their presence in the South African 
population, determine their allelic representation if present and to evaluate LD between them in 
both population groups (Chapter 3). 
 
While -35 SNP and 263 indel were both found to occur in the Black and Caucasian population 
groups, we demonstrated that these polymorphisms were not in strong LD in either population; 
indicating that the -35 SNP was not an appropriate marker for the 263 indel in either group. Our 
findings provided the first description of variability at these polymorphic positions in a sub-
Saharan African population; but more importantly, highlight the necessity of exercising caution 
when applying findings observed in populations of European descent to individuals from 
African populations. African populations are known to exhibit higher levels of genetic 
variability and lower levels of LD than their non-African counterparts (Tishkoff and Williams, 
2002). These genetic characteristics have important implications for medical association studies 
conducted in these populations (Gomez et al., 2014), particularly GWAS studies, which are 
heavily reliant on LD. Our observation that, unlike in Caucasian-Americans (Fellay et al., 
2007), the -35 SNP and 263 indel were not found to be in strong LD in the Caucasian South 
African population, also demonstrates the need to consider the role of demographic history in 
shaping patterns of genetic variability and LD (Rosenberg et al., 2002) when designing 
association studies.  
 
The -35 SNP (Stranger et al., 2005) and 263 indel (Kulkarni et al., 2011)  were first identified 
as a result of their association with HLA-C expression in individuals of European descent. We 
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further identified an additional indel at position 230 within the HLA-C 3’ UTR (rs35877659), 
which we hypothesized could also impact HLA-C expression through modulation of miRNA-
binding (Chapter 3).  Given that HIV-1 Nef selectively downregulates HLA-A and –B to avoid 
lysis of primarily infected cells by cytotoxic T lymphocytes (Collins et al., 1998), but does not 
significantly alter HLA-C expression in order to avoid NK cell-mediated lysis (Cohen et al., 
1999), and that an inverse correlation has been observed between HLA-C expression and HIV-1 
viral load (Apps et al., 2013), we evaluated the impact of genetic variability at the two indel 
positions on HIV-1 control in the Black South African population (Chapter 5). 
 
We found HIV-1 progressors and –controllers to exhibit very similar patterns of genetic 
variability at the 263 indel; suggesting that  either this variant does not significantly alter HLA-
C expression in the Black South African population, or that alterations in HLA-C expression are 
not associated with HIV-1 control in this population. Our observation that progressors and 
controllers exhibit (albeit not significant) differences in allele frequencies at the 230 indel would 
suggest that the former explanation seems more likely. We had previously proposed a model in 
which variability at both the 230 and 263 indels acted in concert to differentially regulate HLA-
C expression (Chapter 3). While we did not functionally verify the validity of this model, the 
observation by others (Corrah et al., 2009; Kulkarni et al., 2011; Apps et al., 2013) that the 
HLA-C alleles with the lowest levels of expression correspond to those in our population with 
insertion alleles at both indel positions, would support our findings.  
 
Although we did not observe a significant association between markers of increased HLA-C 
expression and HIV-1 control (Chapter 4), we can not exclude the possibility that due to 
limitations in our sample size, our study may lack sufficient power to detect associations with a 
small effect size. In this way, the more subtle effects of genetic variability within HLA-C on 
HIV-1 control may be masked by the dominance of those associations detected within the other 
HLA class I loci. The dominant influence of HLA-B in mediating HIV-1 control, particularly in 
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the Black South African population, is well established (Kiepiela et al., 2004; Leslie et al., 
2010). Consistent with this, we have noted strong associations between HIV-1 control and 
genetic variability at the HLA-B locus, involving both specific HLA-B alleles and individual 
polymorphic positions within the locus (Chapter 5).  
 
Our observation that HLA-B*57:03:01 and B*58:01:01 are the alleles most strongly associated 
with HIV-1 control is consistent with multiple reports in the Black South African (Kiepiela et 
al., 2004; Leslie et al., 2010; Tang et al., 2011) and other African (Lazaryan et al., 2006; 
Costello et al., 2008;  Lazaryan et al., 2010) populations. While our findings identifying the 
HLA-B residues associated with HIV-1 control in the Black South African population also 
confirm those observed in both European- (The International HIV Controller Study, 2010) and 
African-American (McLaren et al., 2012) populations and support the idea that peptide selection 
is an important factor in determining the host response to HIV-1 infection (The International 
HIV Controller Study, 2010). Collectively these data (Chapter 4) support the well established 
assertion that a large degree of the genetic variability within HLA-B impacts on HIV-1 control 
as a consequence of its influence on HIV-specific CTL responses (Kiepiela et al., 2007; Miura 
et al., 2009; Berger et al., 2011).   
 
However, our identification of additional residues within both HLA-A and HLA-B that have 
previously been shown to modulate their interaction with receptors on both NK- (Sanjanwala et 
al., 2008) and dendritic cells (Jones et al., 2011), suggests that HLA class I-mediated regulation 
of innate immune function is also involved in HIV-1 control in the Black South African 
population. As innate immune effector cells, NK cells are well established as being critical to 
the early immune response to viral infection (Caligiuri, 2008). However recent findings 
supporting the existence of immunological memory in NK cells (Cooper et al., 2009; Sun et al., 
2009), as well as the identification of KIR-associated amino-acid polymorphisms in the HIV-1 
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sequences of chronically infected individuals (Alter et al., 2011), have led to a re-evaluation of 
the role of these cells in chronic HIV-1 infection.  
 
Accordingly, an association with HIV-1 control has been observed between the NK cell 
receptor, KIR3DL1, and its HLA-Bw4 ligand (Martin et al., 2007). Based on their surface 
expression, KIR3DL1 alleles can be classified as either high expressing (KIR3DL1*h), low 
expressing (KIR3DL1*l) or non-expressed (KIR3DL1*004) (Gardiner et al., 2001: Pando et al., 
2003; Thomas et al., 2008). KIR3DL*h/KIR3DL*h and KIR3DL1*h/KIR3DL1*004 genotypes 
(collectively referred to as KIR3DL1*h/*y) have been shown to be associated with protection 
against HIV-1 disease progression in the presence of HLA-Bw4 molecules with isoleucine at 
position 80 (Bw4-80I) and this protective effect is most pronounced when the HLA-Bw4 
molecule in question is HLA-B57 (Martin et al., 2007). 
 
NK cells from HIV-1 slow-progressors with KIR3DL1 in combination with HLA-Bw4 show 
greater functionality than those from individuals without Bw4 (Kamya et al., 2011). This can 
largely been attributed to the fact that, due to NK cell licensing, individuals with HLA-Bw4 
who express KIR3DL1 on the surface of their NK cells exhibit an increased capacity for ADCC 
relative to individuals without HLA-Bw4 (Parsons et al., 2010; Parsons et al., 2012). Again, the 
highest functional potential is demonstrated by individuals with the KIR3DL1*h/*y/B*57 
genotype (Boulet et al., 2010; Kamya et al., 2011) and NK cells from these individuals are 
better able to inhibit HIV-1 replication in autologous CD4+ T cells than those from individuals 
homozygous for Bw6 or in possession of KIR3DL1*l alleles (Song et al., 2014).  
 
The KIR3DL1*h/*y genotype in combination with HLA-Bw4-80I has also be shown to be 
associated with strong NK responses in elite controllers with reduced HIV-1 Gag-specific CD8+ 
T cell responses (Tomescu et al., 2012). Given that elite controllers often elicit strong HLA-
B57-restricted CTL responses to Gag early in infection (Miura et al., 2009) and that CTL escape 
  
101
mutations within an immunodominant HLA-B57-restricted Gag epitope are known to abrogate 
KIR3DL1 binding to HLA-B57 (Fadda et al., 2011), it is not unreasonable to expect that CTL 
and NK responses in elite controllers with both KIR3DL1 and HLA-B*57 may act 
synergistically, possibly at different points during infection, to limit viral replication (Fadda et 
al., 2011). 
 
While our study could not directly demonstrate this, as we did not examine allelic variability 
within KIR3DL1 and our cohort did not include sufficient individuals in possession of HLA-
B*57 alleles to adequately assess characteristics uniquely associated with these individuals, we 
observed that B*57:03:01 is the allele most strongly associated with HIV-1 control and 
identified of an association between HIV-1 control and amino acids within HLA-B known to 
affect the interaction between KIR3DL1 and its HLA-Bw4 ligands (Chapter 4) - likely through 
differential peptide binding (Sanjanwala et al., 2008). This could suggest that immune 
mechanisms mediated by the KIR3DL1*h/*y/B*57 genotype may influence HIV-1 control in the 
Black South African population and therefore warrant further functional study. 
 
A role for KIR3DL1 in controlling HIV-1 infection in the Black South African population is 
further demonstrated by the observation that HIV-1 progressors possess significantly fewer 
copies of KIR3DL1 per individual than either HIV-1 controllers (Chapter 5) or HIV-1 
uninfected individuals within the Black South African population (Chapter 2). Information 
regarding the patterns of genetic variability within the KIR gene complex in either the Black or 
Caucasian South African populations was not available prior to the commencement of this 
study. Therefore, before we could adequately assess the impact of genetic variability at this 
locus, it was necessary to first describe the KIR gene and haplotype content within the general 
South African population (Chapter 2). 
 
  
102
As anticipated, based on similar studies conducted in other African populations (Norman et al., 
2007; Single et al., 2007; Nakimuli et al., 2013), we found KIR3DS1 and KIR2DS1 to be 
severely under-represented in the Black South African population group relative to Caucasians. 
This observation impacted on our ability to assess the role of variability within the KIR gene 
complex on HIV-1 control, as the co-occurrence of KIR3DS1 and HLA-Bw4 has been reported 
to be favorably associated with HIV-1 disease progression in individuals of European descent 
(Martin et al., 2002a). However, despite this limitation, we were still able to identify patterns of 
KIR genetic variability associated with HIV-1 control (Chapter 5). 
 
Variability in terms of KIR gene content is determined by the presence of two main KIR 
haplotypes (Uhrberg et al., 2002, Martin et al., 2004), which are themselves the product of 
varying combinations of a limited number of centromeric and telomeric gene content motifs 
(Pyo et al., 2010, Jiang et al., 2012; Vierra-Green et al., 2012, Pyo et al., 2013). Our 
examination of the distribution of these motifs and their associated haplotypes within HIV-1 
progressors and –controllers revealed that while HIV-1 progression was associated with 
telomeric motifs lacking KIR3DL1 (and to a lesser extent KIR2DS4), HIV-1 control was 
associated with the heterozygous combination of the centromeric cA01 and cB01 haplotype 
motifs (Chapter 5).  
 
These findings are consistent with previous reports demonstrating an over-representation on the 
Bx 21 KIR genotype and increased frequency of KIR2DS2 and KIR2DS5 in individuals who 
exhibit NK responses to HIV-1 peptides (Tiemessen et al., 2011), as the Bx 21 genotype is 
representative of the heterozygous combination of the cA01|tA01 haplotype and a cB01|tA01 
haplotype containing KIR2DS5. These HIV-specific NK responses have previously been shown 
to be associated with HIV-1 control in Black South African women (Tiemessen et al., 2010). 
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Furthermore, we noted that elite controllers could be distinguished from other HIV-1 controllers 
based on an increased likelihood of being in possession of cB01 haplotype motifs containing 
KIR2DS3 rather than KIR2DS5. As both KIR2DS3 and KIR2DS5 have been demonstrated to 
show markedly reduced levels of surface expression relative to other KIR receptors (Steiner et 
al., 2008; VandenBussche et al., 2009; Steiner et al., 2014) and are not known to recognize 
HLA class I (Chiesa et al., 2008), we hypothesized that the association observed between these 
loci and HIV-1 control was not a consequence of any functional interaction on their part, but 
rather as result of their acting as markers for specific allelic variants of the inhibitory receptors 
KIR2DL1 and/or KIR2DL2 - both of which are known to regulate NK cell function through 
interaction with HLA-C (Colonna et al., 1993; Winter and Long, 1997). 
 
We could not, unfortunately, verify this association experimentally, as we did not examine 
allelic variability with the loci encoding inhibitory KIR receptors. However, it is known that 
KIR2DL1 allelic variants exhibit extensive heterogeneity with respect to their ability to inhibit 
NK cell-mediated cytotoxicity and cytokine secretion (Bari et al., 2009). KIR2DL1 expression 
is also known to be reduced in chronically infected African individuals (Eller et al., 2011) and 
has been shown to inversely correlate with increased ADCC responses in elite controllers (Jia et 
al., 2013). We therefore propose, in light of its potential role in HIV-1 control, that further 
examination of the KIR2DL1 allelic variability present within the Black South African 
population is warranted. 
 
Collectively the data presented within this study provide new insights into the impact of genetic 
variability with the HLA class I loci in the Black South African population - a group severely 
affected by the HIV-1 pandemic - and highlight its influence on HIV-1 control in this 
population. This work also represents the first comprehensive description of genetic variability 
within the KIR gene complex in the Black South African population and identifies the genetic 
variants within this locus associated with HIV-1 control in this population. Even in the absence 
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of functional verification of key findings, these data strongly suggest an important role for these 
molecules in mediating the immune response to HIV-1 and demonstrate the need to better 
understand the role of NK cell-mediated immunity in the control of HIV-1 infection in Black 
South Africans. 
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